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ABSTRACT
 
Poor biopharmaceutical properties such as low solubility and low 
permeability in the gastrointestinal (GI) tract plight many existing drugs and 
new chemical entities, presenting an impediment for efficient drug therapy.
Incorporation of the drug to a delivery system based on a nanostructured 
material is increasingly investigated as a strategy to overcome these 
limitations and to achieve controlled and targeted delivery. Porous silicon 
(PSi) is a promising material for carrier-mediated drug delivery because of its 
biocompatibility, high chemical stability, and facile elimination from the 
body. Moreover, the physicochemical properties of PSi can be tailored by 
variation of the fabrication parameters and surface modifications to suit 
diverse payloads.
Positron emission tomography (PET), a sensitive and quantitative method of 
molecular imaging, is a potent tool for drug delivery system development.
Already at the preclinical stage PET can be employed for the investigation of 
drug delivery carrier biodistribution in vivo, thereby facilitating the selection 
of the most promising material candidates for further development and 
future drug delivery studies. In this dissertation, a direct nucleophilic 
radiolabeling method with a short-lived positron emitter fluorine-18 (18F) 
was developed for three different surface-modified PSi materials: thermally 
hydrocarbonized PSi (THCPSi), thermally carbonized PSi (TCPSi), and 
thermally oxidized PSi (TOPSi). Out of the investigated materials, nanosized 
[18F]THCPSi emerged as the one with the highest potential for imaging and 
drug delivery in terms radiolabeling yield, label stability, and bio­
compatibility in cell models in vitro, and was therefore forwarded to bio­
distribution studies in rats.
After oral administration, [18F]THCPSi nanoparticles were shown to pass 
intact through the GI tract in 4 to 6 hours. Modification of [18F]THCPSi with 
a self-assembled layer of a fungal hydrophobin (HFBII) changed the 
hydrophilicity of the material bringing about bioadhesive properties that 
promoted gastric retention of the protein-coated nanoparticles. Intravenous 
delivery of [18F]THCPSi nanoparticles resulted in their rapid accumulation to 
the liver and spleen alluding to rapid immune recognition and removal of the 
particles from the bloodstream by macrophages of the mononuclear 
phagocyte system (MPS). HFBII-coating of the nanoparticles altered the 
adsorption of plasma proteins to the particle surface, which translated also to 
a change in the biodistribution pattern in vivo. In conclusion, the present 
work establishes 18F-radiolabeled particle tracers as useful means for the 
evaluation of new PSi-based drug delivery systems with PET.
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TIIVISTELMÄ
 
Lääkeaineen biofarmaseuttisesti epäedulliset ominaisuudet, kuten 
niukkaliukoisuus ja huono permeabiliteetti ruoansulatuskanavassa voivat 
muodostua esteeksi tehokkaalle lääkehoidolle. Eräs uusi strategia näiden 
ongelmien ratkaisuun on lääkeaineen liittäminen nanorakenteiseen 
lääkeainekuljettimeen, jonka avulla sitä voidaan annostella säädellysti sekä
kohdennetusti. Huokoinen pii (PSi) on lupaava materiaali lääkeaine­
kuljettimien kehitykseen, sillä sen on osoitettu olevan hyvin bioyhteen­
sopivaa, biohajoavaa sekä kemiallisesti stabiilia. Tämän lisäksi huokoisen 
piin fysikaalis-kemiallisia ominaisuuksia voidaan räätälöidä sen valmistus­
parametrejä muokkaamalla sekä erilaisin pintamodifikaatioin soveltumaan 
useiden erilaisten aineiden kuljetukseen. 
Positroniemissiotomografia (PET) on herkkä ja kvantitatiivinen molekyyli­
kuvantamisen menetelmä, joka soveltuu hyvin lääkeainekuljettimien 
kehitystyön tueksi. Jo kehityksen prekliinisessä vaiheessa positroniemissio­
tomografiaa voidaan käyttää lääkeainekuljettimen biojakauman selvittä­
miseen in vivo, edesauttaen lupaavimpien materiaalikandidaattien valintaa 
jatkokehitykseen ja tuleviin lääkeaineiden annostelukokeisiin. Tässä väitös­
kirjassa kehitettiin suora nukleofiilinen radioleimausmenetelmä lyhyt­
ikäisellä positronisäteilijällä, fluori-18:lla (18F) kolmelle erilaiselle pinta­
muokatulle PSi-materiaalille (THCPSi, TCPSi ja TOPSi). Tutkituista 
materiaaleista nanokokoinen termisesti hydrokarbidoitu [18F]THCPSi 
osoittautui soveltuvimmaksi kuvantamiseen ja lääkeainekuljetukseen 
perustuen sen radioleimauksen saantoon, leiman stabiilisuuteen sekä bio­
yhteensopivuuteen solumalleissa. 
Oraalisen annon jälkeen [18F]THCPSi -nanopartikkelit kulkeutuivat 
muuttumattomina läpi rotan ruoansulatuskanavan 4–6 tunnissa.
[18F]THCPSi:n muokkaus itsejärjestäytyvällä kerroksella sienestä peräisin 
olevaa hydrofobiinia (HFBII) muutti materiaalin hydrofiilisyyttä ja teki siitä 
bioadhesiivisen. Nämä muutokset johtivat proteiinilla muokattujen nano­
partikkelien pidättymiseen mahaan. Suonensisäisen annon jälkeen 
[18F]THCPSi -nanopartikkelit kertyivät maksaan ja pernaan, mikä viittaa 
niiden tunnistamiseen immuunijärjestelmässä ja siitä seuraavaan nopeaan 
poistoon verenkierrosta näissä elimissä olevien makrofagien toimesta.
Päällystäminen hydrofobiinilla johti muutoksiin veriplasman proteiinien 
adsorptiossa nanopartikkelien pinnalle. Tämän seurauksena myös bio­
distribuutiossa havaittiin muutos in vivo. Johtopäätöksenä todettakoon, että 
tässä työssä 18F-radioleimatut partikkelimerkkiaineet on osoitettu hyödylli­
siksi työkaluiksi uusien PSi-pohjaisten lääkeainekuljettimien arviointiin 
positroniemissiotomografian avulla. 
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Introduction
1 INTRODUCTION
 
The development of new materials for drug delivery necessitates the 
thorough characterization and evaluation of these materials in biological 
models: in vitro in cell culture and in vivo in laboratory animals. Molecular 
imaging methods, such as positron emission tomography (PET), can greatly 
facilitate the in vivo evaluation of new materials for carrier-mediated drug 
delivery, because they can be employed essentially in all the steps of drug 
delivery system evaluation from determination of carrier biodistribution to 
assessment of the payload drug release kinetics and proof of therapeutic 
efficacy of the system. This is achieved by the incorporation of positron-
emitting radionuclides like fluorine-18 (18F) to the materials under 
investigation to yield a radiotracer for the imaging studies, or by probing the 
tissue-level biochemical changes evoked by the payload delivery with another 
radiotracer acting on the same system. In contrast to other molecular 
imaging modalities, such as those based on optical detection, the information 
obtained with PET is quantitative and the methodology fully translatable 
from laboratory animals to humans. Furthermore, the inherent sensitivity of 
PET allows for the visualization of the processes of carrier-mediated drug 
delivery with minimal disturbance to the physiological conditions in which 
they occur in vivo. 
Drug delivery systems based on nanomaterials hold great potential for 
improving drug bioavailability, pharmacokinetics, and therapeutic efficacy.
Porous silicon (PSi) is a promising material for the development of new 
micro- and nanoparticle carriers for drug delivery, because of its high initial 
stability in physiological conditions, biocompatibility, biodegradability, and 
variable physicochemical properties that allow for accommodation of a wide 
range of payloads from small-molecule drugs to therapeutic peptides. In 
addition, loading into PSi improves the solubility of many poorly soluble 
compounds, because they are retained in a non-crystalline, amorphous form 
inside the porous network. Furthermore, engineering of the porous silicon 
surface for targeting, imaging, and tailoring of the payload release properties 
is feasible.
In this dissertation, a 18F-radiolabeling method for different surface-modified 
and biofunctionalized PSi materials was developed in order to provide new 
methodology for their evaluation as drug delivery carriers. The developed 
radiotracers were used to study PSi nanoparticle biodistribution and gastro­
intestinal transit in rats after systemic and oral administration. In addition, a 
gastroretentive property endowed on the nanoparticles by a modification 
with a fungal protein was discovered, together with changes on the 
adsorption of plasma proteins on intravenously administered nanoparticles 
as a result of the same modification.
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2 REVIEW OF THE LITERATURE
 
2.1 CARRIER-MEDIATED DRUG DELIVERY
2.1.1 Challenges in drug delivery 
Oral delivery is the administration route of choice for chronic drug therapy 
due to its high patient compliance. However, it is also the most challenging 
one, given the numerous barriers to solubility, stability, and absorption the 
drug must overcome before it enters the circulation from the gastrointestinal 
(GI) tract. The oral bioavailability of a drug is primarily dependent on its 
solubility in the fluids of the GI tract and its permeability across the 
intestinal wall. Based on these properties, drugs can be categorized into the 
four classes of the Biopharmaceutics Classification System (BCS) (Amidon et 
al., 1995), to illustrate their developability as pharmaceuticals. Under­
standably, the most problematic drugs for oral delivery are those for which 
the bioavailability is limited by either low solubility (BCS class II) or low 
permeability (class III), or in some cases, both (class IV). In addition to 
limitations in solubility and permeability, the instability of the drug in the 
harsh conditions of the GI tract can be an impediment to its oral delivery.
This is the case for many biomacromolecules, including therapeutic peptides,
vaccines, and gene medicines (Goldberg et al., 2003). Moreover, rapid 
presystemic metabolism in the gut and liver can limit the bioavailability 
despite adequate absorption from the GI tract (Martinez et al., 2002).
Traditional strategies to overcome poor oral bioavailability have included the 
use of additives such as permeation and solubility enhancers and emulsifiers 
in drug formulations, the formation of an ion pair (salt), complexation,
reduction of drug crystal size, amorphous formulations, and prodrug 
strategies. These have been comprehensively reviewed elsewhere (Fasinu et 
al., 2011). 
Systemic administration, where the drug is introduced directly to the 
bloodstream typically by an intravenous injection, circumvents some of the 
problems of oral delivery. However, controlling the plasma concentration of 
the injected drug in order to obtain the desired therapeutic effect can be 
challenging. The peak concentrations in plasma are typically attained rapidly 
after intravenous delivery, and they decline gradually according to the 
pharmacokinetic profile of the drug. In some cases it would be advantageous 
to modify the pharmacokinetics in order to avoid adverse effects associated 
with high peak concentrations, or to attain prolonged drug effects at the 
target site. This is achieved for example by incorporation of the drug to long-
circulating liposomes yielding a sustained release of the drug (Chang et al.,
2012). Furthermore, new ways to target drugs to the desired site of action 
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after intravenous administration are constantly sought as means to alleviate 
side effects and to improve therapeutic efficacy, as for example in the case of 
many anticancer agents (Pirollo et al., 2008).
2.1.2 The potential of particle-based drug delivery systems 
A new era in drug delivery research began more than 30 years ago when the 
first controlled drug delivery systems emerged as an alternative to 
conventional formulation strategies for tailoring of drug therapy (Hoffman,
2008). In short, a controlled drug delivery system is a device that can provide 
control over the rate and duration of drug release, and in many instances a 
possibility for targeted delivery (Vallet-Regí et al., 2007). From drug-eluting 
shunts to implanted reservoirs to drug-loaded nanoparticles, controlled drug 
delivery systems come in all shapes and sizes, as well as in a plethora of 
materials. An area of particular interest and intense development over the 
past decade has been drug delivery systems based on nano- and micro-
particles. By convention, the term nanomaterial is used in reference to 
materials with at least one dimension in the range of 1–100 nm (Lövestam et 
al., 2010). In the field of nanobiomedicine, however, the term is used rather 
liberally to describe structures falling below 1 !m on the dimensions and 
having often a nanoscale substructure. Herein, the term nanoparticle is used 
for particles below 1 !m in diameter, and the term microparticle for particles 
with a diameter of >1 !m.
The tremendous potential of particle-based drug delivery systems stems from 
the possibility to influence the loading, the release, and the biofate of a drug 
in multiple ways by tailoring the physicochemical properties of the carrier 
material. Ideally, the drug delivery system should meet the following criteria 
(Slowing et al., 2008):
•	 Biocompatibility, i.e. the absence of adverse effects related to the 
carrier material.
•	 High degree of incorporation of the payload.
•	 Negligible or zero premature release of the payload before the 
target site.
•	 Specificity for a cell type or tissue, or targeting ability.
•	 Controlled release of the payload with an adequate rate to 
attain an effective local concentration. 
Because of their unique properties such as small size and high surface area,
nanomaterials can readily respond to some of these requirements, and can as 
a result of their variable chemistry be engineered further to meet the rest of 
them (Singh et al., 2009). Many particle-based drug delivery systems are
based on materials that are expected to exhibit a high degree of bio­
compatibility, including biomacromolecules (e.g. chitosan), polymers, lipids,
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and inorganic materials like silicon and hydroxyapatite. Furthermore,
biodegradation of the material is often desirable for safe disposal and 
elimination of the carrier from the body. Nevertheless, the question of 
nanomaterial toxicity especially during chronic exposure like in the case of 
continuous drug therapy is a pertitent problem in nanobiomedicine, and 
stringent evaluation of the material toxicity is urged (De Jong et al., 2008).
The nanoscale substructure of many materials allows for high loading degree 
of the therapeutic payload. Furthermore, confinement to the drug delivery 
carrier often increases the solubility of a drug, thus aiding efficient 
incorporation. The release kinetics can be tailored for example by covalent 
binding of the drug to the carrier, stimuli-reponsive release mechanisms (e.g.
those sensitive to a change in pH), or by encapsulation of the carrier with a 
slowly degrading coating. Targeting and tissue specificity can be achieved by 
decoration of the particle surface with antibodies or receptor ligands, such as 
folate. In addition, particle-based carriers can be designed to have either 
immunosuppressive (e.g. long-circulating stealth nanocarriers) or immuno­
stimulatory properties like those of nanoparticle-based vaccines 
(Dobrovolskaia et al., 2007). Furthermore, certain nanocarriers are known to 
extravasate efficiently into tumors simply because of the enhanced 
permeation and retention (EPR) -effect made possible by the special 
structure of the tumor vasculature and the small particle size (Maeda et al.,
2000).
Mesoporous inorganic materials are promising candidates for the 
development of particle-based drug delivery systems, because they can 
answer to the above-mentioned prerequisities of a successful drug delivery 
carrier (Arruebo, 2011). Typically based on silica (silicon dioxide, SiO2) and 
porous silicon (PSi), these materials consist of a network of channels, or 
‘pores’, studding the bulk material. By definition, the pores in mesoporous 
materials range from 2 to 50 nanometers in diameter (Rouquerol et al., 
1994). The porous network endows the material with high pore volume and 
surface area, which translate to a high capacity for drug adsorption and 
loading (Tang et al. 2012, Salonen et al., 2008). Furthermore, the pores often 
have a narrow size distribution contributing to uniform and repeatable drug 
loading and release kinetics. The tunability of the pore diameter, orientation,
and interconnectivity by variation of the fabrication parameters – especially 
for silica-based materials – allows for the accommodation of a wide array of 
payloads (Wang, 2009). Analogously, the particle size can range from a few 
nanometers to microns enabling administration in both intravenous and oral 
routes. Additional advantages of mesoporous materials include the 
possibility to modify the surface chemistry in various ways to include for 
example targeting moieties or imaging tags, and the relatively high chemical 
and mechanical stability of the materials in biological enviroments (Arruebo,
2011). 
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2.1.3 	 Mucoadhesive and gastroretentive dosage forms 
A special case of particle-based drug delivery systems are bioadhesive dosage 
forms, i.e. drug formulations that exhibit attachment to biological 
membranes. When this adhesion is prefenretial for mucous membranes, the 
system is referred to as mucoadhesive (Lee et al., 2000, Asane et al., 2008). 
The rationale behind the design of mucoadhesive drug delivery systems for 
the oral route is that the tight contact of the system and the mucosal 
membrane allows for a prolonged residence time of the carrier at the site of 
payload absorption contributing to high local concentration and enhanced 
absorption of the drug (Ponchel et al., 1998). Traditionally mucoadhesive 
dosage forms have been based on polymers, such as cross-linked polyacrylic 
acids, carboxymethyl cellulose, and alginate, which swell in contact with the 
mucous membrane and can interlock with the mucus glycoproteins by 
electrostatic interactions and hydrogen bonding (Peppas et al., 1996). In the 
oral route, mucoadhesive dosage forms can be used to prolong the gastric 
residence time, which is advantageous for certain drugs that are either 
intended for local delivery to the gastric mucosa, that have a narrow 
absorption window in the upper small intestine, or that are unstable or 
poorly soluble in the gut (Hoffman et al., 2004). Such formulations are 
referred to as gastroretentive. Alternative strategies for prolonging the 
gastric residence time of a drug include floating and size-increasing drug 
formulations. The common mode of action for these delivery systems is to 
slow down the passage of the dosage form to the small intestine by 
mechanical entrapment in the stomach (Streubel et al., 2006).  
2.1.4 	 Plasma protein adsorption to intravenously administered 
particles 
After introduction to the circulation, the surface of a nanoparticle becomes 
decorated with adsorbed proteins and other blood constituents, such as 
lipids. The adsorbed plasma proteins form a corona encasing the particle, the 
composition of which varies depending on the physicochemical properties 
(i.e. surface chemistry, charge, hydrophobicity, shape, and size) of the 
particle (Aggarwal et al., 2009). Furthermore, due to the difference in 
surface-to-volume ratio, the identities and quantities of the adsorbed 
proteins can be different between a nanoparticle, microparticle, and a flat 
surface of a given material (Roach et al., 2006). However, the exact 
mechanism of the formation of the corona is not yet well understood, in part 
because of the lack of comprehensive evaluation and reporting of the above-
mentioned parameters in studies regarding plasma protein adsorption to 
intravenously administered particles. Nevertheless, a growing body of 
evidence is being aquired for the impact of the plasma protein corona on 
cellular interactions, immune recognition, and biodistribution of nano­
particles (Serda et al., 2011, Dobrovolskaia et al., 2008, Moghimi et al.,
2001). 
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According to the current understanding, the formation of the plasma protein 
corona consists of two phases. The first phase is initiated by the transient 
binding of abundant but low-affinity plasma components such as serum 
albumin and fibrinogen to yield a freely and rapidly exchanging ‘soft’ corona.
These are in the second phase gradually replaced by less abundant plasma 
proteins (e.g. complement factors) that bind at a higher affinity, leading to 
the formation of a slowly exchanging, relatively immobile ‘hard’ corona
(Cedervall et al., 2007, Walczyk et al., 2010, Monopoli et al., 2011). Since the 
lifetime of the hard corona is in the order of hours for many materials, it has 
been indicated to be responsible for the observed effects on the interactions 
of the nanomaterial in biological systems (Walczyk et al., 2010).
Furthermore, as the corona is formed, the immediate properties (e.g. surface 
chemistry, charge, hydrophobicity) of the nanoparticle do not necessarily 
contribute directly to the interactions, because they can be masked by the 
accumulating protein layer. To date, around 50 proteins of the human 
proteome of circa 3700 proteins have been identified in nanoparticle plasma 
protein coronas (Aggarwal et al., 2009, Lynch et al., 2007). These can be 
roughly divided into opsonins, i.e. proteins such as immunoglobulin G (IgG) 
whose adsorption promotes the immune recognition of the nanoparticles and 
their uptake to the cells of the mononuclear phagocyte system (MPS), and 
dysopsonins, such as serum albumin and apolipoproteins, that have been
shown to increase the circulation times of nanoparticles (Owens et al., 2006,
Ogawara et al., 2004). The MPS (also known as the reticulo-endothelial 
system, RES) consists of macrophages in the liver (known as Kupffer cells) 
and in the spleen, which take up foreign material by phagocytosis directed by 
the adsorption of opsonins. Consequently, modification of the nanoparticle 
surface with poly(ethyleneglycol) (PEG) and other polymers has been widely 
investigated as means towards reducing the binding of opsonins in order to 
create longer-circulating nanoparticles (Moghimi et al., 2001). On the other 
hand, the covalent binding of certain apolipoproteins can be used to facilitate 
nanoparticle-mediated drug delivery across the blood-brain barrier (Kreuter
et al., 2007).
2.2	 POROUS SILICON (PSi) MATERIALS FOR
BIOMEDICAL APPLICATIONS
2.2.1 Preparation and surface modification of PSi 
The porous form of the element silicon (porous silicon, PSi) was discovered 
somewhat accidentally in the 1950s by researchers at Bell Laboratories 
during investigations on the electrolytic shaping of silicon discs for semi­
conductor device manufacture (Uhlir, 1956, Turner, 1958). Dismissed as a 
curiosity at the time, the mechanism of the porous layer formation during the 
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electrochemical etching of crystalline silicon in hydrofluoric acid (HF) was 
described only in the early 1990s (Canham, 1990, Lehmann & Gösele, 1991). 
The porous structure was shown to bestow the material with photo­
luminescence at room temperature due to the widening of the Si band gap 
because of a quantum confinement effect (Canham, 1990). Today, the 
electrochemical etching, or “anodization”, of silicon in dilute HF solutions 
still remains the most frequently used method of PSi fabrication (Salonen & 
Lehto, 2008). In the simplest setup for the electrochemical etch, a silicon 
wafer is used as the anode and a platinum wire as the cathode. By application 
of electric current, a porous layer is generated on the surface of the silicon 
wafer following the dissolution mechanism depicted in Figure 1. Notably the 
prerequisities for the dissolution of crystalline Si appear to be the presence of 
holes (i.e. unoccupied states on the valence band) and HF (Lehmann & 
Gösele 1991). Consequently, the dopant type and doping level of the Si 
substrate have a strong impact on the formation of the PSi layer, with 
electron-rich n-type substrates typically requiring additional illumination 
during the anodization in order to yield a porous structure (Cullis et al.,
1997). In addition, the thickness of the PSi layer, the degree of porosity, and 
pore morphology can be controlled by the fabrication parameters. Current-
free stain etch and photochemical etch methods (reviewed by Salonen & 
Lehto, 2008), relying solely on the use of chemicals and oxidizing agents 
such as HNO3 or intense light as hole injectors, are alternatives to PSi 
generation by anodization. They are, however, not as reproducible as 
anodization, and often result in a less uniform porous structure and a thinner 
PSi layer, which has hampered their utility for PSi fabrication for biomedical 
applications (Anglin et al., 2008). However, the introduction of some less 
common additives like vanadium pentoxide to the etching solution might 
circumvent some of these problems (Kolasinski et al., 2010).  
Figure 1. The dissolution mechanism of Si in hydrofluoric acid for the formation of
PSi. Adapted from (Lehmann & Gösele, 1991)
The freshly etched (“as-anodized”) PSi surface is terminated with silyl 
hydrogens (Si–Hx, x=1–3) with oxygen and fluorine typically present as trace
impurities (Burrows et al., 1988). However, the reactive hydride-terminated 
surface is vulnerable to oxidation and other deteriorating effects of the 
environmental and storage conditions including humidity, temperature, and 
atmospheric composition, leading to “aging” i.e. alterations in the properties 
of the PSi layer over time (Salonen et al., 2008, Beckmann, 1965). Therefore, 
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the as-anodized surface is stabilized using a chemical surface treatment,
most commonly either controlled oxidation or introduction of Si–C bonds
through thermal (hydro)carbonization or hydrosilylation (Petrova-Koch et
al., 1992, Salonen et al., 1997, Salonen et al., 2002, Salonen et al., 2004,
Buriak, 1999). The surface chemical treatments are typically designed to 
preserve the porous structure, but they can bring about alterations in the 
pore dimensions, specific surface area, and material hydrophilicity (Anglin et 
al., 2008). 
Thermal oxidation of as-anodized PSi results in the formation of three 
oxygen-containing surface species: –OySi–Hx via oxidation of the Si–Si 
backbonds, Si–OH in which the oxygen is inserted into the Si–H bond, and 
Si–O–Si created through oxidation of the Si–Hx surface with ejection of 
hydrogen (Mawhinney et al., 1997). As expected, the degree of oxidation in 
thermally oxidized PSi (TOPSi) is dependent on the temperature, and the 
treatment is typically carried out at temperatures ranging from 250–300°C,
required for the onset of backbond oxidation to 700–1000°C used for
complete oxidation and restoration of the material photoluminescence
(Salonen & Lehto, 2008, Petrova-Koch et al., 1992). In addition, oxidation 
can be achieved using anodic, chemical, and photochemical methods (Cullis
et al., 1997). Notably, the oxidation converts the hydrophobic as-anodized 
PSi surface into hydrophilic, which is expected to translate into increased 
biocompatibility (Salonen et al., 2008, Santos et al., 2010). On the other
hand, the hydrophilic surface is more prone to hydrolysis in aqueous 
environments, leading to dissolution of the material (Jarvis et al., 2012).
Compared to oxidized PSi, creation of Si–C bonds on the PSi surface yields a 
remarkably stable surface, capable of withstanding harsh conditions like 
boiling strong bases and solvents (Linford et al., 1995, Buriak et al., 1998).
The observed stability likely arises from the smaller difference between the 
electronegativities of carbon and silicon compared to that between silicon 
and oxygen. Various methods for the introduction of carbon to the PSi 
surface have been reported. The efforts of Buriak and co-workers have 
focused on chemical hydrosilylation of the PSi surface with alkenes and 
alkynes via a Lewis acid -catalyzed mechanism (Buriak et al., 1998, Buriak et 
al., 1999a). The advantages of hydrosilylation include the possibility to 
derivatize the PSi surface with a plethora of organic groups via creation of a 
stable Si–C bond. Furthermore, the reactions can be carried out at ambient 
temperature thus avoiding potential damage of the porous structure. Since 
the process requires illumination, it has been proposed as a possibility for 
photopatterning of PSi substrates (Buriak, 1999b). As alternatives for the 
Lewis acid -mediated reaction, catalyst-free thermal hydrosilylation and 
derivatization via organometallic addition have been explored (Boukherroub
et al., 2001, Song et al., 1998).
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Aside the wet chemistry methods, thermal hydrocarbonization and carbon­
ization of PSi surface with gaseous hydrocarbons has been reported (Salonen
et al., 2002, Salonen et al., 2004). Small hydrocarbon molecules such as 
acetylene diffuse rapidly to the porous structure of PSi contributing to a 
higher surface coverage for the treatment than that typically obtained with 
the chemical hydrosilylation methods (Salonen & Lehto, 2008). Further­
more, the reaction temperature can be adjusted in order to obtain either a 
fully carbonized Si–C termination (thermally carbonized PSi, TCPSi) at 
temperatures above 600°C, or a hydrocarbon-terminated surface (thermally 
hydrocarbonized PSi, THCPSi) at temperatures below 600°C with a mixture 
of acetylene and nitrogen (Salonen et al., 2002, Salonen et al., 2004).
Curiously, the THCPSi surface remains hydrophobic, but is abruptly turned 
hydrophilic with increasing the reaction temperature to yield TCPSi. A 
shared drawback of the thermal carbonization treatments is that the 
photoluminesence of PSi is quenched or lost altogether.
As the standard jigsaw pieces of peptide and nucleic acid chemistry, amino or 
carboxylic acid surface terminations might be desirable for the design of PSi­
based biomaterials. Arroyo-Hérnandez et al. have reported the amino­
functionalization of PSi surface for immobilization of biomolecules by 
grafting with 3-aminopropyltriethoxysilane (APTES) (Arroyo-Hernández et 
al., 2003). Godin and co-workers have in turn utilized the APTES linker for 
grafting of PSi surface with PEG (Godin et al., 2010). Carboxylic acid 
functionalization can be achieved for example with hydrosilylation with 
undecylenic acid and radical coupling of sebacic acid (Boukherroub et al.,
2002, Sciacca et al., 2010). Further decoration of the carboxylic acid 
-terminated PSi surface with chitosan oligomers and anti-cancer agent 
doxorubicin has since been reported (Sciacca et al., 2011, Wu et al., 2008).
Size reduction of the top-down-produced PSi is typically carried out by the 
lift-off of the PSi layer from the etch substrate by electropolishing (an abrupt 
rise in the etching current) followed by ultrasonic fracture and ball milling
(Anglin et al., 2008, Salonen et al., 2005). Microparticles are commonly 
sieved to the desired size fraction, whereas centrifugation is used for 
nanoparticles. The surface treatments can be performed either on the free­
standing films or particles. In addition, photolithography can be applied for 
the fabrication of PSi particles with precisely defined size and shape 
(Chiappini et al., 2010). The somewhat less economical use of the substrate 
in photolithographic methods could however be considered a disadvantage.
2.2.2 PSi in biological systems 
The early discoveries on the ability of PSi to support the growth of
hydroxyapatite (Canham, 1995, Canham et al., 1996), and cultures of living 
cells (Bayliss et al., 1997, Chin et al., 2001) quickly led to an increasing 
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interest on the suitability of the material for biomedical applications. The 
biomedical applications employing PSi materials reported to date have
included biosensing based on the optical properties PSi, biomolecular 
screening, implantable biomaterials, brachytherapy, and drug delivery
(Palestino et al., 2008, Nijdam et al., 2007, Rosengren et al., 2000, Goh et 
al., 2007, Santos et al., 2011). One of the most acclaimed features of PSi is its 
degradation to monomeric silicic acid, Si(OH)4, in biological fluids and 
within the body, resulting in efficient elimination in urine (Carlisle, 1970).
Furthermore, as silicon is an essential nutrient and a relatively abundant
element in the diet, it is unlikely to pose toxicity even after administration at
concentrations necessary for attaining a therapeutic effect with the payload
(Jugdaohsingh et al., 2002). The degree and rate of biodegradation in PSi 
can be modified by the porosity and pore size, and surface decoration of the 
material (Salonen et al., 2008). Curiously, porosity exceeding 70% yields PSi 
materials that dissolve easily in simulated body fluids (with the exception of 
gastric fluid), whereas porosity less than 70% results in slowed bio­
degradation – to the point that very low porous PSi and macroporous PSi are 
virtually bioinert, like bulk silicon (Salonen et al., 2008). Decoration of the 
PSi particle surface with for example 1-dodecyne, dextran, or PEG also 
stabilizes the material against degradation in simulated and true biological 
fluids and in vivo (Godin et al., 2010, Canham et al., 1999, Park et al., 2009).
The in vitro biocompatibility of PSi has been investigated in several cell lines.
In these studies, cytotoxic effects dependent on particle size, concentration,
surface chemistry and the cell type have been found (Santos et al., 2010, Choi
et al., 2009, Low et al., 2010). In an investigation on the in vitro immuno­
genicity of different Si surface morphologies in human blood-derived 
monocytes, nanoporous silicon was found to elicit responses equivalent to 
those of tissue culture polystyrene (Ainslie et al., 2008). Based on the results 
of a systematic study with THCPSi, TCPSi, and TOPSi microparticles in
human Caco-2 cells (widely used as a model for intestinal permeation and 
absorption), Santos et al. (2010) postulate that the mechanism of PSi– 
induced cytotoxicity is disruption of the cell energy metabolism by depletion 
of adenosine triphosphate (ATP) and generation of reactive oxygen species 
(ROS) as a result of direct particle–cell interactions. Surface modifications of 
the PSi materials, especially thermal oxidation that yields a hydrophilic 
surface, decrease the production of ROS resulting in higher biocompatibility 
of the respective materials in vitro (Santos et al., 2010, Chin et al., 2001, Low
et al., 2010). This is likely due to the decrease in the reduction potential of 
the PSi surface compared to that of freshly etched hydrogen-terminated PSi
(Wu et al., 2011). Internalization of surface-modified PSi microparticles has 
been shown in human endothelial cells and macrophages by both phago­
cytosis and macropinocytosis (Serda et al., 2009b). Stimulation with 
inflammatory cytokines resulted in increased uptake in both cell types,
whereas PEGylation of the microparticles prevented internalization.
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Furthermore, the different cell types were shown to be selective for the initial 
zeta potential of the studied PSi particles, despite the fact that particle 
opsonization in serum had rendered all the particles with a negative surface
charge. Additionally, endothelial cells with internalized PSi microparticles 
maintain their cellular integrity and normal proliferative capacity over 
several days, with the microparticles retained in single-particle endosomal 
vesicles (Serda et al., 2009a).  
Reports on the biocompatibility of PSi nanoparticles have been scarce to date
and limited primarily to the evaluation on the effects of drug-free nano­
particles on cancer cells compared to their counterparts loaded with 
anticancer agents such as doxorubicin (Wu et al., 2008, Park et al., 2009).
Notably, the cytotoxicity evaluation in these studies has been carried out 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, which is not optimal for the cytotoxicity testing of PSi because 
of the spontaneous redox reactions occurring between the testing reagent 
and the material (Laaksonen et al., 2007, Low et al., 2006). Choi et al. 
(2009) in turn have shown that 3–5 nm luminescent silicon nanoparticles 
reduced the viability of murine RAW 264.7 macrophages more than 
0.1–3 !m microparticles did, but the inflammatory response of the cells was 
lower towards nanosized PSi than towards microparticles.
Evaluation of the in vivo biocompatibility and biodistribution of PSi particles 
has been included in only a few studies to date. Neither acute nor subchronic 
exposure to intravenously administered APTES-modified and oxidized PSi 
microparticles altered the renal and hepatic functions in mice, and resulted 
in no detectable change in the plasma levels of several inflammatory cyto­
kines (Tanaka et al., 2010a). Based on the tissue Si content determined with
inductively coupled plasma atomic emission spectroscopy (ICP-AES), the 
intravenous administration of APTES-PSi microparticles loaded with siRNA­
containing liposomes to an orthotopic mouse model of ovarian carcinoma 
resulted in biodistribution of the microparticles primarily to the liver and the 
spleen (Tanaka et al., 2010b). Similar results were obtained with dextran-
modified oxidized PSi nanoparticles in healthy mice after single intravenous 
injection of 20 mg kg–1 of the nanoparticles (Park et al., 2009). A preliminary 
evaluation of the toxicity of the PSi nanocarrier at the abovementioned dose 
included in the study showed no adverse effects in terms of body weight and 
tissue pathology over the course of 4 weeks. Interest in the use of PSi in 
ophthalmic implants has spun investigations on the biocompatibility of the 
material with tissues of the eye. Oxidized, aminosilanized, and polycapro­
lactone-encapsulated PSi membranes supported the growth of human lens 
epithelial cells and corneal explants in vitro, and were well tolerated when 
implanted under the conjunctiva in rats (Low et al., 2009, Kashanian et al.,
2010). Additionally, the implants were shown to support the expansion of 
human epithelial cell xenografts also in vivo in the rat eye (Low et al., 2009). 
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2.2.3 Drug delivery using PSi 
Drug loading into and release from PSi particles has been primarily studied 
in vitro using model drugs that cover a range of physico-chemical properties
(pKa, log P, and solubility) and BCS classes, such as the non-steroidal anti­
inflammatory drugs (NSAIDs) indomethacin and ibuprofen, as well as 
griseofulvin, antipyrine, ranitidine, furosemide, and itraconazole (Salonen et 
al., 2005, Wang et al., 2010, Bimbo et al., 2011a, Kinnari et al., 2011). Drug 
loading into PSi materials is most commonly achieved with passive 
adsorption by immersion of the PSi particles or films in excess volume of 
concentrated drug solution prepared in a suitable solvent (Salonen et al.,
2008). Other, less common methods include covalent attachment and 
trapping by oxidation of the PSi surface, which have been reviewed by Anglin 
et al. (2008). These methods are, however, fairly irreversible, and possibly 
therefore have not attracted interest similar to that of drug concentration by 
adsorption. The degree of drug loading and affinity of a given drug for the PSi 
carrier is strongly dependent on the surface chemistry of the material and 
properties of the drug in question, and can consequently be affected by the 
loading parameters, including solvent selection, drug concentration, pH,
temperature, and time (Salonen et al., 2008). Furthermore, expansion of the 
pore size might be necessary in order to accommodate a given payload
(Anglin et al., 2004). In addition, some drugs have been shown to react
vigorously with certain PSi materials, exemplified by the oxidation of as-
anodized PSi by antipyrine (Salonen et al., 2005). Analogously, the stability 
of the drug payload during long-term storage and in tablet formulations of 
PSi particles can be affected by the material properties (Kinnari et al., 2011,
Limnell et al., 2007, Tahvanainen et al., 2012). Moreover, the properties of 
the PSi matrix (e.g. rate of biodegradation, capping of the pore openings) can 
provide a means for temporal control of drug release (Anglin et al., 2004,
Perelman et al., 2008).
Drug loading into PSi particles has been shown to improve drug dissolution
(Salonen et al., 2005, Limnell et al., 2007). Thermal analysis and nitrogen 
sorption studies with PSi microparticles loaded with ibuprofen have revealed 
that the PSi-loaded drug is present in two thermodynamically different states 
inside the pores: a disordered state close to the pore wall, and a crystalline 
one at the center. A third, crystalline state can be found on the particle 
surface (Riikonen et al., 2009). The presence of the disordered !-layer 
renders the pore–confined drug crystals with a high lattice energy that is 
thought to contribute to the observed increases in both drug solubility and 
dissolution rate (Yu, 2001). Furthermore, the thickness of the !-layer is
impacted by both the pore diameter and the surface chemistry, illustrating 
how the loading and dissolution of the payload could be tailored by careful 
tuning of the material properties. However, the presence of the crystallized 
surface fraction complicates the determination of the loading degree, as some 
methods cannot distinguish between the drug contained inside the pores and 
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in the surface fraction. The most accurate quantification is often obtained 
with a combination of different methods including nitrogen sorption,
thermogravimetry, high performance liquid chromatography (HPLC), and 
differential scanning calorimetry (DSC) (Salonen et al., 2008, Salonen et al.,
2005). The improvements in the dissolution behavior of drugs encapsulated 
into PSi particles have been shown to translate into enhanced permeation 
across biological barriers, such as a Caco-2 monolayer simulating the 
intestinal epithelium (Bimbo et al., 2011a, Kaukonen et al., 2007). In vivo,
significant increase in oral bioavailability of indomethacin upon loading into 
thermally oxidized PSi microparticles has been observed (Wang et al., 2010).  
Aside small molecule drugs, successful encapsulation and release of several 
peptides and proteins including insulin, papain, and gramicidin A, using PSi 
has been shown in vitro (Foraker et al., 2003, Prestidge et al., 2007,
Prestidge et al., 2008). In vivo, Kilpeläinen and co-workers have 
demonstrated sustained release of peptides Melanotan II, a melanocortin 
receptor agonist, and a ghrelin antagonist from THCPSi microparticles after 
subcutaneous administration by monitoring the respective physiological 
effects of the peptides on heart rate and blood pressure in rats, and on water 
and food intake in mice (Kilpeläinen et al., 2011, Kilpeläinen et al., 2009). In
both studies, a delayed and/or prolonged effect was attained with the 
particle-loaded peptide compared to the peptide in solution. Furthermore,
drug-free THCPSi microparticles did not produce adverse cardiovascular 
effects, and did not increase the plasma concentrations of several cytokines 
after administration corroborating the safety of the material. In addition to 
peptide payloads, also secondary nanoparticles can be loaded and 
transported using PSi. Tasciotti et al. (2008) have described a multistage 
delivery system consisting of stage 1 porous silicon microparticles (S1MPs) 
loaded with a stage 2 nanoparticle (S2NP) payload, such as quantum dots or 
single-walled carbon nanotubes. Tanaka and co-workers have demonstrated 
sustained gene silencing and antitumor effects in a mouse model of ovarian 
carcinoma by small interfering RNA (siRNA) delivered by the multistage 
delivery system with siRNA-containing neutral nanoliposome payload
(Tanaka et al., 2010b). Recently, conjugation of a near infrared (NIR) dye to 
the S1MPs for optical imaging of microparticle distribution in mice was 
reported (Tasciotti et al., 2011).
2.2.4 Biofunctionalization with hydrophobins
Hydrophobins are small, amphiphilic surface-active proteins from 
filamentous fungi. In fungal biology, they are typically expressed in processes 
where the organism transits from aqueous environment to air, such as 
dispersal through sporulation and hyphae (Wösten, 2001). This arises from 
the capability of hydrophobins to self-assemble on hydrophobic/hydro­
philic–interfaces creating an amphiphatic layer (Linder, 2009) Based on the 
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solubility of this layer and the protein hydropathy plots, hydrophobins are 
divided into two classes: class I of highly insoluble hydrophobins (e.g. SC3 of 
Schizophyllum commune), and class II consisting of hydrophobins (e.g.
Trichoderma reesei HFBI and HFBII) that dissolve with ease in aqueous 
solutions and dilute ethanolic and detergent solutions at concentrations 
exceeding 100 mg ml–1 (Cox et al., 2007). The structure of T. reesei HFBII is 
shown in Figure 2. A distinct feature of HFBII is the relatively large 
hydrophobic patch consisting of the hydrophobic aliphatic amino acid 
residues of the two "-hairpin loops that project to the surface instead of being 
embedded in the hydrophilic domains of the protein.
Figure 2. The tertiary structure of T. reesei HFBII. The amino acid residues
composing the hydrophobic patch are indicated in yellow. The !-helix is colored in 
green for orientation in the space filling model. Structure retrieved from the RCSB
Protein Data Bank (www.pdb.org, Berman et al., 2000) with PDB ID 1R2M
(Hakanpää et al., 2004).
The capability for reversal of surface wettability through hydrophobin self-
assembly underlies the interest in the proteins for biomaterial applications,
including prevention of biofouling and promotion of material bio­
compatibility in biomedical devices (Janssen et al., 2002, Scholtmeijer et al.,
2002, Hektor et al., 2005), and new formulation strategies for poorly soluble 
drugs (Haas Jimoh Akanbi et al., 2010, Valo et al., 2010, Valo et al., 2011). In
addition, modification with hydrophobins has been employed to disperse
hydrophobic materials such as Teflon® powders, single-walled carbon
nanotubes, and graphene sheets efficiently in aqueous solutions (Lumsdon
et al., 2005, Kurppa et al., 2007, Laaksonen et al., 2010). Engineered 
variants of hydrophobins have been used in the immobilization of drug 
nanoparticles on nanofibrillar cellulose, patterning of nanoelectronic devices,
and in the development of DNA-binding conjugates by coupling with 
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multivalent dendrons (Varjonen et al., 2011, Laaksonen et al., 2009,
Kostiainen et al., 2006). De Stefano and co-workers have concentrated their 
efforts specifically on the modification of silicon and PSi surfaces with a class 
I hydrophobin from Pleurotus ostreatus for masking of the surface in the 
KOH wet–etch process and secondary immobilization of enzymes and other 
proteins to the hydrophobin-coated surface for biosensing applications (De 
Stefano et al., 2007, De Stefano et al., 2008, De Stefano et al., 2009). 
Furthermore, improvement in the biocompatibility of THCPSi microparticles 
in vitro in cell models of intestinal absorption has been demonstrated. In the 
same study, the lack of impediments to indomethacin release from 
hydrophobin-modified THCPSi microparticles was corroborated, illustrating 
the feasibility of the approach for carrier-mediated drug delivery (Bimbo et 
al., 2011b). Interestingly, hydrophobins have even been implicated in the 
prevention of immune recognition of inhaled fungal spores in mice 
(Aimanianda et al., 2009), but the property has not been investigated for 
systemically administered nanoparticles prior to the present work.
2.3 RADIOLABELED TRACERS FOR PET IMAGING
2.3.1 Principle and use of positron emission tomography (PET) 
Positron ("+) emission tomography is a non-invasive molecular imaging 
method based on the detection of two coincident 511 keV annihilation gamma 
quanta arising from the decay a radioactive positron-emitting isotope
coupled to a pharmacologically or otherwise biologically active compound,
referred to as a radiotracer. Henceforth, the term radiotracer will be used in 
this review, as a synonym for the equally ubiquitous term imaging probe in 
the literature. The term radiopharmaceutical will be reserved for formulated 
radiotracer preparations approved for diagnostic use in humans 
(Vallabhajosula, 2009). The radiotracer is administered to the study subject
(e.g. a human volunteer or patient, or a laboratory animal), where it 
sequestrates to organs and tissues according to the distribution of its target 
(e.g. a receptor protein) or biology, like in the case of confinement of radio­
labeled albumin to the blood pool or accumulation of radioactive fluoride to 
the bone (Phelps, 2000, Hoffend et al., 2005, Charkes et al., 1979). Tomo­
graphic distribution of the annihilation events is recorded with an array of 
scintillation detectors placed around the subject (Figure 3). Because of its 
high spatial resolution (5–6 mm in clinical tomographs) and the possibility 
to measure the exact concentration of the radiolabeled tracer in the tissues by 
means of the radioactivity, PET is considered both a sensitive and a
quantitative molecular imaging method (Cherry, 2001). However, PET 
imaging typically needs to be accompanied by a computer tomography (CT) 
or an MRI (magnetic resonance imaging) scan, since no anatomical informa­
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tion on the localization of the radioactivity can be obtained with PET alone.
The advent of the PET technique was preceded by the development of 
methods for cyclotron production of short-lived positron-emitting radio­
isotopes, including 18F, 11C, 13N, and 15O. Today, largely due to the increased 
demand for facile radiosynthetic routes to peptide and antibody tracers and 
isotopes that can be produced without a cyclotron, the selection of available 
isotopes has expanded to include positron-emitting radiometals (e.g. 68Ga, 
64Cu, 89Zr), and other radionuclides with relatively long half-lives, such as 
124I. The most common positron-emitting radionuclides reported in the 
literature for either clinical or preclinical applications and their properties 
are collected in Table 1. In addition to these, several non-conventional 
positron emitters are available (Pagani et al., 1997).  
Figure 3. The principle and setup of positron emission tomography.
The evolution from the early experimental instruments to the first 
comprehensive computerized systems in the 1970s onset the clinical use of 
PET (Phelps et al., 1975, Phelps et al., 1978). Advances in detector design and 
read-out electronics enabled the miniaturization of the instrumentation for 
the construction of dedicated PET scanners for preclinical imaging of small 
laboratory animals such as rats and mice at a spatial resolution of 2–3 mm
(Lecomte et al., 1996, Cherry et al., 1997, Humm et al., 2003). Today, both 
preclinical and clinical PET imaging studies are being embraced also by the 
pharmaceutical industry for all stages of drug development, from lead 
compound optimization in the early phases to providing surrogate markers 
more sensitive than clinical measures for late phase evaluation in humans
(Matthews et al., 2012). Oncology, cardiology and neurology are the main 
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areas of application of PET imaging. However, an astounding 90% of all 
clinical PET studies are performed with a single tracer, 18F-radiolabeled 
2-fluoro-deoxyglucose ([18F]FDG), a glucose analog for imaging of energy 
metabolism. This highlights perhaps one of the foremost limitations to 
employment of PET, which is the limited availability of different radio-
pharmaceuticals, as [18F]FDG is the sole radiopharmaceutical produced in 
the majority of medical cyclotron facilities in operation today globally
(Coenen et al., 2010). Furthermore, only a handful of these facilities are able 
to cater to the radiopharmaceutical chemistry needs for both diagnostics and
research, posing obviously a hindrance for the wider employment of the 
imaging modality to basic research (Wester, 2007). 
Radionuclide t1/2 E!,max !+ yield Production
keV %
11C 20.4 min 960.5 100 C; 14N(p,!)11C
13N 9.97 min 1200 100 C; 16O(p,!)13N
15O 2.04 min 1732 100 C; 15N(p,n)15O
18F 109.8 min 634 96.7 C; 20Ne(d,!)18F
18O(p,n)18F
64Cu 12.7 h 653 17 C; 64Ni(p,n)64Cu
68Ga 67.7 min 1899 89 G; 68Ge/68Ga
89Zr 3.3 d 901 23 C; 89Y(p,n)89Zr
124I 4.18 d 2138 23 C; 124Te(p,n)124I
124Te(d,2n)124I
C, cyclotron; G, generator
Table 1. Properties of selected positron-emitting radionuclides.
2.3.2 Considerations for PET radiotracer development 
2.3.2.1 Microdosing principle
The principle of microdosing in PET studies was introduced by Bergström 
and co-workers in 2003 (Bergström et al., 2003). The concept of micro-
dosing arises from the high specific radioactivity (SA, or the radioactivity-to­
mass -ratio, denoted typically as GBq !mol–1) of PET radiotracers, which 
translates to a very low mass dose in the order of nanomoles (corresponding 
to 3–10 !g in most cases) of the radiotracer in a typical dose of radioactivity 
(150–800 MBq) used in human PET studies. The administered low mass 
dose is considered to be subpharmacological, i.e. small enough to avoid 
eliciting a pharmacological response, including toxicity, to the drug.
Therefore, even potentially harmful substances, such as drugs of abuse and 
entirely new chemical entities can be administered as radiotracers. Besides 
high SA, another prerequisite of successful microdosing study is that the 
radiotracer and the substance it traces have the same chemical identity.
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Therefore it is justified that the substance under study is forwarded to studies 
in humans as the “radiolabeled version” without carrying out the 
conventional often time-consuming and expensive preclinical evaluations of 
pharmacology and toxicology. Positron emission tomography microdosing is 
therefore emerging as a boon for earlier selection of promising drug 
candidates based on their pharmacokinetics in animal models and in first-in­
man studies for further development (Lappin et al., 2008). However, it must 
be borne in mind that not all PET studies are microdosing studies. For 
example, demonstration of dose linearity (i.e. that the tissue-to-plasma ratio 
of the radiotracer concentration is linear regardless of the administered dose) 
requires titration of the administered dose close to the therapeutic dose with 
the non-radiolabeled compound (Wagner et al., 2011).
2.3.2.2 Selection of isotope and radiolabeling strategy 
Despite the common mode of decay, not all positron emitters are created 
equal in terms of imaging properties. Some, such as 68Ga have higher 
positron energy (Table 1), which means that the positron will venture 
further away from the site of emission prior to annihilation, constituting thus 
a limit for the spatial resolution of images and increasing the radiation 
burden to the subject (Pagani et al., 1997, Cho et al., 1975). Furthermore, the 
isotope is not necessarily a pure "+ emitter like in the case of 124I, and the 
other modes of decay might complicate image reconstruction and raise 
dosimetry concerns (Pentlow et al., 1991). In addition, the isotope needs to 
be selected bearing in mind the time course for the biological process one 
intends to follow with the tracer. An extreme example would be certain long-
circulating monoclonal antibodies that need 2–4 days before they have 
accumulated to the target tissue in sufficient amounts to permit imaging,
leaving only the ones with long half-lives like 89Zr up for the task (Verel et al.,
2003). On the other hand, the very short half-life of 15O allows for several 
PET scans to be performed on the same subject on the same day with 
reasonably low radiation burden. The half-lives of 11C and 18F are certainly 
sufficient for the imaging of receptor density or rate of amino acid utilization
after intravenous administration of the radiotracer, the most common 
applications of PET imaging.
The availability of positron-emitting isotopes of elements across the periodic 
table translates to versatile possibilities for PET radiochemistry. Because of 
its convenient 109.8-minute half-life that allows for multistep radiosynthesis 
and transport of the final product, 18F has been the positron emitter of choice 
for many radiotracers. Furthermore, the relatively low positron energy and 
100% "+ yield (Table 1) of 18F enables imaging at high spatial resolution.
18F-radiolabeled tracers are, however, in many cases fluorinated structural 
analogs, and the effect of the fluorine substitution to the pharmacological 
profile of the compound needs to be rigorously evaluated (Park et al., 1994). 
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On the contrary, the isotopes of carbon, oxygen, and nitrogen are the 
building blocks of natural compounds and organic chemistry, and the 
respective radiotracers will behave exactly like their unlabeled counterparts 
(Miller et al., 2008). The sole limitation for the use of 11C, 13N, and 15O is the 
short half-life that necessitates on-site production of the isotope and allow 
only for single-step reactions, or no synthesis at all. Nevertheless, even 15O 
can, despite its 2-minute half-life, be derivatized further to form 15O-water
used as a tracer for blood flow (Ter-Pogossian et al., 1969). The positron-
emitting radiometals are primarily used in applications where one-step 
coordination chemistry is feasible, as in the radiolabeling of proteins and 
nanoparticles. In addition, certain radiometals can serve as radiotracers 
without further radiosynthesis, as illustrated by the use of 64Cu to study 
disorders of copper metabolism (Blower et al., 1996). 68Ga has become a
radiometal of particular interest, as a result of the availability of the 
generator-produced isotope to research groups that have no in-house access 
to a cyclotron (Fani et al., 2008). Furthermore, the properties of 68Ga are 
favorable for the generation of good quality images even with less sensitive 
imaging equipment (Pagani et al., 1997). Nevertheless, as for all radiometals,
the introduction of the metal-binding ligands to the molecule of interest can 
potentially influence its behavior in biological systems.
Finally, the maximum specific radioactivity that can be obtained in a routine 
production of the isotope is different for the different positron emitters. This 
has a direct impact on the specific activities at which radiotracers labeled 
with the respective isotope can be produced. The required SA of the radio­
tracer in turn depends on the experimental paradigm. For example, only 11C 
and 18F are amenable for use in for example neuroreceptor studies, for which 
a high SA corresponding to a low mass dose of the radiotracer are paramount
(see section 2.3.2.3), whereas most nanoparticle and antibody tracers can be 
used with substantially lower SA. Typical specific activities of PET tracers fall 
in the range of 5–500 GBq !mol–1 (Miller et al., 2008).
2.3.2.3 Target selection for imaging of carrier-mediated drug delivery 
The selection of the biological target for which the radiotracer is developed 
needs to be based on solid understanding of the biomolecular basis of the 
process to be studied. This is fairly straightforward in the established 
applications of PET imaging, such as oncology, where knowledge on the 
expression of possible targets (e.g. genes, proteins) in disease pathology is 
often available (Wester, 2007). Experimental design for PET imaging of 
carrier-mediated drug delivery, however, presents an interesting problem for 
target selection. The question is which “player” of the system should be 
radiolabeled: the carrier material, the payload, or could perhaps a preexisting 
radiotracer be utilized as a surrogate marker for payload delivery in vivo? A 
drawback of PET in this respect is that all of the available radiolabels emit 
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photons at 511 keV, and their identification based on the detected gamma 
energy is not possible unlike in SPECT where registration of the energy 
allows for multiple-isotope, and consequently multiple-target, imaging in one 
session (Rudin et al., 2003). Different aspects of the carrier-mediated 
process can be visualized using a different tracer. Firstly, by radiolabeling the 
drug delivery carrier, its biodistribution and pharmacokinetics can be 
studied. This allows for the determination of circulation time and accumula­
tion to target and non-target tissues, estimation of carrier immunogenicity 
from the MPS organ data, and assessment of carrier elimination (Liu et al.,
2012). The choice of the right animal model for the initial carrier bio­
distribution studies is important, because the carrier distribution might be 
fundamentally different in healthy and diseased animals, as illustrated by the 
EPR effect resulting in the accumulation of nanocarriers to tumor xenografts 
due to leaky tumor vasculature (Iyer et al., 2006).  
Radiolabeling of the payload would allow for the visualization of the kinetics 
of payload delivery, and the effects of the carrier on payload biodistribution 
and bioavailability. However, like the radiolabeling of the carrier, the radio­
labeling of the payload often necessitates the development of a new radio­
tracer, because the selection of available PET radiotracers is limited. Further­
more, in is not in all cases feasible to develop a radiotracer based on the 
stucture of a known drug one intends to use as the payload. In addition, the 
time span for the payload incorporation to the carrier material may fall 
beyond the limits set by the half-life of the commonly used PET radio­
nuclides, rendering the approach unsuccessful in most cases. Additionally,
the loading kinetics is bound to be different for tracer and therapeutic doses 
of the payload.
Perhaps the most efficient strategy would therefore be to employ an already 
existing PET radiotracer to probe the biological effects brought upon by the 
delivery of a therapeutic dose of the payload incorporated to the carrier. The 
use of imaging biomarkers (i.e. changes in tracer accumulation) as surrogate 
markers has several advantages over the use of a clinical marker such as a 
change in tumor volume or blood pressure. First, the imaging biomarkers are 
more sensitive to subtle changes in the physiology, and can often detect these 
changes earlier than a clinical biomarker would. Second, they allow for the 
longitudinal follow-up of the same subject, circumventing some of the 
problems associated with inter-individual variation. Combined to the carrier 
biodistribution and pharmacokinetics studies using radiolabeled carriers the 
approach is envisioned to provide a comprehensive proof-of-concept on the 
suitability of the respective material for carrier-mediated drug delivery and 
further development.
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2.3.3 Preclinical studies in the course of radiotracer development 
A hallmark of PET is its translationality, the possibility to use the exactly 
same in vivo imaging technique and the same radiotracer across species 
(Phelps, 2000). Preclinical studies in experimental animal models have a 
pivotal role in the development of new radiotracers, because they constitute 
the only possibility to extract the amount radioactivity from the animal 
tissues for correlation with the data obtained with PET imaging. Preclinical 
studies can be used for radiotracer target validation, and investigations of
metabolism, pharmacokinetics, and dosimetry (Haaparanta et al., 2004,
DeGrado et al., 2002). Animal models of human disease are valuable tools 
for target validation and monitoring of therapeutic interventions. The 
development of dedicated high-resolution positron emission tomographs has 
enabled the imaging of mice, and consequently increased the availability of 
transgenic animal models for radiotracer evaluation (Cherry, 2001). Besides 
rats and mice, larger animals such as rabbits, dogs, swine, and non-human 
primates are used in preclinical PET imaging studies, especially in applica­
tions where the small body size of laboratory rodents is a limitation or the 
use of a species closer to humans is advantageous. Furthermore, since PET 
enables the longitudinal follow-up of the same animal, it allows for the 
design of more clinically relevant experiments and ultimately decreases the 
number of animals needed by increasing the statistical power through 
reduction of complications arising from inter-individual variation (Rudin et 
al., 2003). The use of small animal PET imaging, however, rarely obviates 
the need for dissection for determination of ex vivo biodistribution at the 
early stages of the radiotracer development. Ex vivo autoradiography of 
tissue sections or, in some cases, the whole carcass is a useful method for 
acquiring additional information on radiotracer biodistribution and target 
occupancy at the sub-organ level, and for correlation with histological 
analysis (Laitinen et al., 2010).  
The animal studies are complemented with several in vitro assays, including 
metabolism studies in cell and enzyme preparations (e.g. liver microsomes,
S9 fraction) and tissue homogenates (Matusch et al., 2006, Seneca et al.,
2010), tracer uptake studies in cell models (Krasikova et al., 2011), in vitro
autoradiography, and evaluations of radiolabel stability in physiologically 
relevant media (e.g. plasma, simulated body fluids, buffer solutions). The 
latter is of particular importance, because the radiolabeled tracer, detached
free radiolabel, and radiolabeled metabolites cannot be distinguished from 
one another by PET imaging or tissue radioactivity measurements. In the in
vitro and ex vivo radiolabel metabolism assays the chemical form of each 
radioactive species can be determined using analytical methods, such as 
high-pressure liquid chromatography, mass spectrometry, and thin-layer 
chromatography (Haaparanta et al., 2004, Ma et al., 2010). In addition, in
vitro studies with material of human origin, for example post-mortem brain 
sections, can be used to establish species differences in the behavior of the 
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radiotracer early on and obtain data with direct relevance to human studies 
(Hall et al., 1994). 
2.3.4 Nanoparticle tracers radiolabeled with positron emitters 
An illustrative list of reported studies carried out with nanoparticles radio­
labeled with positron-emitting radionuclides to date is collected in Table 2. 
As it can be seen, several different types of nanomaterials have been radio­
labeled and imaged with PET. Majority of the studies concern probe 
development for preclinical oncology, reflecting the general outlook of nano­
biomedicine (Ting et al., 2009). In addition, nanoparticle tracers for cardio­
vascular and pulmonary imaging have been developed (Nahrendorf et al.,
2008, Liu et al., 2009).
Another apparent trend in the development of nanoparticle radiotracers is 
that they are almost exclusively endowed with the capability for multi-
modality imaging, with for example PET/MRI, or PET in conjuction to an 
optical imaging method, such as near-infrared (NIR) or fluorescence
imaging. The tracers are most commonly dual-modality probes, but 
combinations of three and even four modalities to a single nanoparticle have
been reported (Zhou et al., 2011, Li et al., 2012). The plausible explanation 
for the interest in multimodality imaging especially in preclinical studies is 
that the other imaging modality can be selected to complement PET in this 
paradigm, for example to enable imaging of cellular interactions of the nano­
material which occur beyond the resolution of PET. Furthermore, when 
compared to small animal imaging studies using optical methods, PET is 
certainly inferior in throughput in terms of the number of animals that can 
be imaged simultaneously or with one batch of the radiotracer. Therefore,
inclusion of an optical imaging probe might be desirable despite the other­
wise poorer imaging characteristics when compared to PET. Perhaps the 
most elegant multimodality strategy is the combination of PET and MRI, two 
powerful and fully translational imaging modalities into one tracer allowing 
both anatomical registration of the nanoparticle localization at high resolu­
tion and quantification of the nanoparticle concentration. Another important 
feature of PET/MRI probes is that the MRI visualization of the nanoparticles 
enables the demonstration of the radiolabel stability in vivo, which is of 
utmost importance when drawing conclusions on nanoparticle pharmaco­
kinetics, biodistribution, and elimination based on the radioactivity signal
(Hong et al., 2009). In addition to the incorporation of several imaging 
modalities, most nanoparticle radiotracers are equipped with targeting 
moieties (e.g. RGD-peptide, folate) in order to increase target penetration 
(Cai et al., 2007, Rossin et al., 2005). Incorporation of a therapeutic payload 
to generate a theranostic (therapeutic and diagnostic) probe has also been 
investigated (Li et al., 2012).
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The longer-lived "+-emitters, especially 64Cu, have been predominantly used 
for radiolabeling of nanoparticles. This is likely to have been driven by the 
need for a sufficiently long half-life for the follow-up of nanoparticle 
sequestration after administration, as well as the availability of the isotope 
also for laboratories without an immediate access to a cyclotron facility. In 
addition, the chelators for radiometal labeling can be introduced to polymer 
and lipid nanoparticles already during the monomer synthesis, facilitating 
one-step radiolabeling of the assembled nanoparticle (Pressly et al., 2007).
Furthermore, the FDA (U.S. Food and Drug Administration) approval of the 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelating 
agent has promoted the use of radiometals for the radiolabeling of nano­
particles also for preclinical studies (Liu et al., 2012). Nevertheless, 18F is 
emerging as an alternative, and simple, fast strategies for the incorporation 
of 18F to inorganic nanoparticles have recently been developed (Liu et al.,
2011, Jauregui-Osoro et al., 2011). Also conventional methods of 18F-radio­
chemistry have been used for radiolabeling of liposome and polymer nano­
particles with 18F-fluoroethyltosylate (Marik et al., 2007, Herth et al., 2009).
2.4 RADIOCHEMISTRY WITH FLUORINE-18
2.4.1 Production of 18F 
18F is introduced into radiolabeling reactions in two chemical forms: either as 
[18F]fluoride ([18F]F–) or as molecular fluorine in the form of [18F]F2 gas 
(Elsinga, 2002). Both of these forms can be directly obtained from a cyclo­
tron, 18F-fluoride from an 18O(p,n)18F nuclear reaction with irradiation of an 
enriched (>97%) [18O]H2O target, and [18F]F2 either from a 20Ne(d,#)18F 
reaction, or an 18O(p,n)18F reaction in Ne:F2 and 18O:F2 mixed gas targets 
(Ruth et al., 1979, Casella et al., 1980, Nickles et al., 1984). Since 
[18F]fluoride is produced in a no-carrier-added (n.c.a.) form that readily 
dissolves in the target water, the specific radioactivity of [18F]F– is high,
typically exceeding 185 GBq !mol–1 (Cai et al., 2008), and reaching values as 
high as 5180 GBq !mol–1 (Solin et al., 1988). On the contrary, non-radio­
active F2 gas needs to be added as a carrier in [18F]F2 production, resulting in 
considerably lower SA, in the order of 1 GBq !mol–1 (Teare et al., 2010).
However, an alternative strategy for the production of [18F]F2 from [18F]F– 
via a post-target generation and subsequent breakdown of [18F]CH3F using 
an electric discharge obviates the need for added carrier and markedly 
improves the SA of [18F]F2 (Bergman et al., 1997).
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Imaging 
Radionuclide Nanomaterial Labeling strategy modalities Application Reference
18F Liposome 18F-fluoroalkylation PET Biodistribution (Marik et al., 2007)
Block copolymer 18F-fluoroalkylation PET Biodistribution (Herth et al., 2009)
Upconversion nanophosphor Inorganic interaction PET, MRI, UCL Multimodality probe (Liu et al., 2011)
Nanodiamond [18F]SFB conjugation PET Biodistribution (Rojas et al., 2011)
Aluminum hydroxide and 
hydroxyapatite
Inorganic interaction and/or -OH 
displacement PET Biodistribution
(Jauregui-Osoro et 
al., 2011)
Iron oxide core shell Click chemistry PET, CT, NIR Biodistribution (Devaraj et al., 2009)
Phospholipid-encapsulated
quantum dot [
18F]FPyMe conjugation PET, fluorescence Biodistribution (Ducongé et al.,2008)
64Cu Liposome BAT conjugation PET Pharmacokinetics (Seo et al., 2008)
Comb copolymer DOTA conjugation PET Biodistribution
Gold DOTA conjugation PET Pharmacokinetics, biodistribution (Xie et al., 2010)
Phospholipid-encapsulated SPIO DOTA conjugation PET, MRI Pharmacokinetics, biodistribution (Glaus et al., 2010)
Quantum dot DOTA conjugation PET, NIR Biodistribution (Cai et al., 2007)
Single-walled carbon nanotube DOTA conjugation PET, Raman Pharmacokinetics, biodistirbution (Liu et al., 2007)
68Ga Latex Coordination to carboxylic acid residues PET, MRI Biodistribution (Cartier et al., 2007)
76Br Dendrimer Chloramine T radiobromination PET Imaging of !v " 3 integrin expression
(Almutairi et al.,
2009)
124I MnFe2O4 Chloramine T radioiodination PET, MRI Sentinel lymph node imaging (Choi et al., 2008)
Polymer Chloramine T radioiodination PET Biodistribution (Simone et al., 2012)
89Zr Single-walled carbon nanotube Desferrioxamine B conjugation PET, NIR Pharmacokinetics, biodistirbution,therapy
(Ruggiero et al.,
2010)
Table 2. Examples of nanoparticle tracers developed for PET imaging.
(Shokeen et al.,
2011)
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2.4.2 Radiolabeling with 18F 
2.4.2.1 General aspects 
The availability of 18F only as nucleophilic fluoride ion or electrophilic 
fluorine restricts the possibilities for 18F radiochemistry. In general, the 18F 
radiolabel can be introduced to compounds either directly or by coupling of a 
18F-containing prosthetic group, the radiolabeling synthon (Elsinga, 2002,
Cai et al., 2008). Regardless of the radiosynthetic approach, the introduction 
of the 18F radiolabel as late as possible in the synthesis is advantageous,
because it reduces the delay between the end of bombardment for the
production of the isotope and the end of synthesis, thus minimizing the loss 
of radioactivity through radioactive decay. However, regioselective radio­
labeling with 18F often necessitates that certain functional groups in the pre­
cursor molecule are protected when the radiolabel is introduced and the 
protecting groups are subsequently removed, leading in most cases to multi­
step radiosyntheses. Therefore, the non-radioactive synthesis precursors are 
preferably designed to be regioselectively radiolabeled either with (nucleo­
philic) 18F directly or with a 18F-containing synthon in an one-step reaction 
followed by rapid deprotection.
Both nucleophilic and electrophilic fluorination reactions are utilized for the 
synthesis of radiopharmaceuticals currently in clinical use. The lower SA of 
the starting material, the need for special equipment for the handling of
highly reactive [18F]F2, and the possibility of unselective reactions have,
however, limited the attractiveness of electrophilic fluorinations, and nucleo­
philic substitution reactions have dominated in 18F radiochemistry (Miller et
al., 2008, Cai et al., 2008). Nevertheless, electrophilic 18F-fluorodemetalla­
tion of electron-rich arylstannanes is the preferred radiosynthetic route to 
18F-radiolabeled amino acids, including 18F-6-fluoro-3,4-dihydroxy-L­
phenylalanine ([18F]FDOPA), the gold standard for PET imaging of cerebral 
dopamine metabolism (Dollé et al., 1998). In addition, N-18F-fluoro-N-alkyl­
sulfonamides and 18F-radiolabeled Selectfluor (1-chloromethyl-4-fluoro­
diazonia-bicyclo[2.2.2]-octane bis-(tetrafluoroborate)) derivatives synthesi­
zed from high-specific-activity [18F]F2 have been investigated as more 
selective reagents towards electrophilic 18F-fluorinations (Teare et al., 2010,
Satyamurthy et al., 1990). Furthermore, the generation of 18F-radiolabeled 
palladium(IV)fluoride complexes from [18F]fluoride to serve as electrophilic 
18F-fluorinating reagents was recently reported (Lee et al., 2011).
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2.4.2.2 Radiolabeling with [18F]fluoride 
The reactivity of [18F]fluoride is strongly reduced by solvation into the 18O­
water. Therefore, removal of the target water to decrease the degree of 
hydration of the [18F]F– ion is a necessary step in order to render the ion a 
strong enough nucleophile for nucleophilic substitution reactions (Landini et 
al., 1989, Vlasov, 1993). This is commonly achieved by trapping the 
[18F]fluoride from the target water onto an ion exchange resin followed by 
elution with weak aqueous base, most typically K2CO3. The [18F]F– is 
subsequently dried by an azeotropic distillation with acetonitrile. Phase-
transfer catalyst such as the kryptand Kryptofix 2.2.2 (4,7,13,16,21,24­
hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane) is added together with a K+ 
counterion in order to solubilize the fluoride in organic solvents and increase 
its nucleophilicity for the subsequent reactions (Coenen et al., 1985,
Hamacher et al., 1986). Alternatively large cations such as Cs+ or tetrabutyl 
ammonium (t-Bu4N+) can be used without a kryptand (Jewett et al., 1988).
Mild basic conditions are typically maintained in order to prevent the loss of 
[18F]F– nucleophilicity through protonation.
Direct 18F-fluorination with [18F]F– is the radiosynthetic method of choice for 
compounds for which either an aliphatic bimolecular (SN2) or aromatic 
(SNAr) nucleophilic substitution is feasible (Cai et al., 2008). Aliphatic 
substitution reactions with [18F]F– are usually carried out very efficiently with 
sulfonate (e.g. triflate, mesylate, tosylate or nosylate) leaving groups. Other 
halogens, such as Cl and Br, may also serve as leaving groups, but the 
radiochemical yields tend to be lower in this case (Elsinga, 2002). The 
substitution typically occurs at the !-carbon in a carbonyl group, cyanide or 
sulfonamide. In addition, an isotopic exchange of 18F for a 19F atom is 
possible, but because the 18F-radiolabeled product and the 19F-containing 
precursor are chemically identical and cannot be separated, radiotracers 
produced this way always have lower specific radioactivity (Wagner et al.,
2009). Furthermore, ring opening, as for the 2,3’-anhydrothymidine pre­
cursor in the radiosynthesis of [18F]FLT (3’-deoxy-3’-18F-fluorothymidine), is 
feasible with [18F]F– (Machulla et al., 2000). The prerequisite for efficient
aromatic nucleophilic substitution with 18F is the presence of a good leaving 
group (e.g. nitro or trimethylammonium) at a para- or ortho-position to an 
activating substituent, such as –NO2 or carbonyl on the aryl ring (Cai et al.,
2008, Le Bars et al., 1998). Halogens can also serve as leaving groups, but 
their leaving group ability is generally inferior for this reaction type, except 
for heteroaromatic substitutions such as to a pyridine (Dolci et al., 1999).
Interestingly, in the absence of an “ortho effect” from an activating 
substituent that would direct the substitution to the respective aryl ring 
yielding the 18F-fluoroarene, the incorporation of 18F to the desired position 
can be directed by reaction with a diaryliodonium salt containing an 
electron-rich heteroaryl ring, such as 2-thienyl (Pike et al., 1995, Martin-
Santamaria et al., 2000). 
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In cases where a direct substitution of 18F– is not feasible, the radiolabel 
needs to be introduced by means of a radiolabeling synthon derived from 
[18F]fluoride. An important group of synthons are the 18F-fluoroalkylating 
reagents, including [18F]fluorethyltosylate, and [18F]fluoroethyl and 
[18F]fluoromethyl bromides, which can be used for the radiolabeling of 
amino, hydroxyl, and thiol functions. These are typically prepared from 
!,"-bifunctional aliphatic precursors containing halide or sulfonate moieties 
via a direct aliphatic substitution (Block et al., 1987). o- and p-substituted 
[18F]fluorobenzaldehydes generated using the same approach have proven 
out to be useful synthons for introduction of a 18F-fluorophenyl moiety, and 
as precursors to more reactive [18F]fluorobenzyl halides (Lemaire et al., 1992,
Iwata et al., 2000). Furthermore, p-substituted 18F-fluoroarenes (e.g. –Br,  
–Li, –NH2, and –N2+) as radiolabeling synthons have been reported (Cai et 
al., 2008). In addition, several selective synthons such as N-succinimidyl-4­
18F-fluorobenzoate ([18F]SFB) and its derivatives have been developed for 
18F-radiolabeling of proteins and other biomacromolecules (Vaidyanathan
et al., 1992, Cai et al., 2006). 
2.4.2.3 Radiolabeling synthons containing silicon 
Silicon-containing radiolabeling synthons are a relatively new development
in 18F radiochemistry. Si-18F chemistry is envisioned to have potential for the 
development of facile, one-step “kit-like” 18F-labeling reactions, primarily for 
the radiolabeling of peptides (Schirrmacher R. et al., 2007, Smith et al.,
2011). The high affinity of silicon for fluorine suggests that silyl halides could 
be useful as labeling precursors for the corresponding 18F-fluorosilanes in 
relatively mild conditions, rendering the approach feasible for the labeling of 
biomolecules (Schirrmacher R. et al., 2006). Additionally, once formed, the 
Si–18F bond could potentially be more resistant towards hydrolytic cleavage
than a C–18F one, because of its higher bond energy and the efficient 
stabilization of the lone electron pair of fluorine by silicon (Streitwieser et al.,
1992). However, the initial report on the low hydrolytic stability of Si–18F 
bond in [18F]fluorotrimethylsilane in vivo by Rosenthal and co-workers 
(Rosenthal et al., 1985) decreased interest in the approach, despite their 
proposal to circumvent the problem by using a more sterically hindered 
fluorosilane. [18F]fluorotrimethylsilane could, however, be used as a source of 
nucleophilic 18F for the synthesis of [18F]FDG (Hutchins et al., 1985).
Ting and co-workers have reported a high-yield synthesis of 18F-alkyltetra­
fluorosilicates from corresponding triethoxysilane precursors and [18F]F–
with added fluorine carrier (Ting et al., 2005). Notably, unlike conventional 
radiolabeling with [18F]F– the reaction proceeds in aqueous solutions, at 
room temperature, and at a pH range compatible with peptide labeling. In
addition, the stability of the 18F-radiolabel was reported to be sufficient for 
40 

  
  
  
  
 
 
 
  
 
 
 
 
 
 
  
incorporation into a PET radiotracer. Despite having used carrier fluorine 
that lowers the SA, the authors postulated that the approach could be 
adapted to no-carrier-added conditions to yield high-specific-activity 
18F-alkyltetrafluorosilicates for PET imaging applications. A similar strategy
using alkoxytrialkylsilane precursors bearing phenyl, methyl, and t-butyl 
substituents has been reported by Choudhry et al. (Smith et al., 2011,
Choudhry et al., 2006). In this study, rapid radiolabeling with 18F was 
deemed feasible for all the synthesized trialkylfluorosilanes, but only the 
ones with “bulky” substituents (i.e. phenyl and t-butyl) demonstrated 
sufficient hydrolytic stability of the Si–F bond.
Promising approaches towards one-step synthesis have been aquired from 
the work of Schirrmacher and co-workers. They have successfully radio­
labeled several peptides with 18F using an isotopic 19F-18F exchange reaction 
on para-substituted di-tert-butylphenylfluorosilanes (Schirrmacher R. et al.,
2006). Intuitively, an isotopic exchange does not strike across as the most 
effective strategy for radiolabeling to a high SA. This was indeed the case 
when the 19F-fluorosilane was directly coupled to the peptide prior to the 
radiolabeling reaction (Schirrmacher R. et al., 2006). However, the problem 
was circumvented by the generation of a p-(di-tert-butyl-18F-fluorosilyl)­
benzaldehyde synthon radiolabeled via isotopic exchange that was sub­
sequently coupled to an amino-oxy –derivatized peptide precursor, resulting 
in over a 100-fold increase in the SA (Schirrmacher E. et al., 2007). The 
research group has proceeded with the development of new di-tert-butyl­
fluorosilyl synthons, including an N-succinimidyl-3-(di-tert-butyl-18F-fluoro­
silyl)benzoate one based on the structure of [18F]SFB, a widely used protein 
18F-radiolabeling agent (Iovkova et al., 2009, Kostikov et al., 2012). The 
radiolabeling of rat serum albumin with the developed 18F-fluorosilyl­
benzoate allowed for the PET imaging of the blood pool in the rat, illustrating 
the feasibility of the approach for radiolabeling of peptide tracers for PET.
Simultaneously with the work described above, Mu and co-workers 
developed alkylsilane (t-butyl, isopropyl, and methyl) precursors with alkoxy,
hydroxy, and hydride leaving groups and either an alkyl or aryl linker for 
18F-radiolabeling of peptides (Mu et al., 2008). Arriving to the same 
conclusion on the effect of the steric hindrance to the Si–18F bond stability, a 
di-tert-butylsubstituted fluorosilane with a phenyl linker emerged as the 
most stable configuration. This was further corroborated by an elegant 
follow-up study by Höhne and co-workers, where the hydrolytic stability of 
the Si–F bond in several of the alkylsilanes was determined and correlated 
with the respective bond length from theoretical calculations (Höhne et al.,
2009). They concluded that in fluorosilanes bearing bulky substituents, such 
as t-butyl and isopropyl, the difference between the Si–F bond length in the 
unhydrolyzed fluorosilane and in a pentacoordinate hydrolysis intermediate 
(Figure 4) was smaller than in less sterically hindered fluorosilanes,
possibly explaining the observed resistance towards hydrolysis.
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Figure 4. The SN2 mechanism of organofluorosilane hydrolysis. Adapted from
(Höhne et al., 2009)
Curiously, in spite of the comparable stability of both di-isopropyl and di­
tert-butyl -substituted synthons alone, only the di-tert-butylfluorosilyl one 
showed sufficient hydrolytic stability in physiological conditions both in vitro
and in vivo when coupled to a bombesin peptide (Höhne et al., 2008).
However, the high lipophilicity bestowed on the radiolabeled tracers by the 
di-tert-butyl –substituted synthons can potentially restrict their utility for 
development of PET imaging probes (Höhne et al., 2008). Efforts to solve 
this issue by the incorporation of more hydrophilic moieties to the structure 
without compromising the radiolabel stability are underway (Kostikov et al.,
2011). 
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3 AIMS OF THE STUDY
The motivation for the present study was to develop new methodology for the 
evaluation of porous silicon as a carrier material for drug delivery 
applications in vivo with PET. Specifically the aims were:
1)	 to develop a 18F-radiolabeling method for different surface-modified 
PSi materials (I), 
2)	 to investigate the in vivo behavior of PSi nano- and microparticles 
using the developed tracers (II–IV), and 
3) to gain insight on the particle properties governing biodistribution
after administration via oral, intravenous, and subcutaneous routes, 
and the effect of biofunctionalization with T. reesei hydrophobin 
thereupon (II–IV).
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Materials and methods
4 MATERIALS AND METHODS
 
This section describes the materials and methods used in the present work.
In part the methodology is presented in greater detail than in the respective 
original publications I–IV. 
4.1 MATERIALS
4.1.1 Porous silicon particles and films 
The porous silicon nano- and microparticles used in this study were prepared 
at the Laboratory of Industrial Physics, Department of Physics and Astro­
nomy, University of Turku. Additionally, free-standing thermally hydro-
carbonized PSi (THCPSi), thermally carbonized PSi (TCPSi), and thermally 
oxidized PSi (TOPSi) films were used in the spectroscopic characterization of 
the 18F-radiolabeled materials in study I. The preparation methods are 
described in detail in the original publications I and II. The PSi particles 
were characterized with nitrogen sorption at 77 K using a TriStar 3000 gas 
sorption apparatus (Micromeritics Inc.) The specific surface area, pore 
volume, average pore diameter, and degree of porosity were calculated from 
the the measured isotherms using the Brunauer–Emmett–Teller (BET,
Brunauer et al., 1938) and Barrett–Joyner–Halenda (BJH, Barrett et al.,
1951) theories, respectively. Physical properties of the particles used in 
studies I–IV are collected in Table 3. 
Specific surface Pore Average pore Nominal 
Material area volume diameter size Study
m2/g cm3/g nm
TCPSi 262 1.099 16.8 1–38 !m I
TOPSi 260 1.1 16.3 1–38 !m I
THCPSi	 311 1.036 13 1–38 !m I
202 0.51 9 142 nm II
323 0.48 7.4 <100 nm III, IV
Table 3. Physical properties of the PSi materials used in the radiolabeling studies
(I–IV)
4.1.2 Reagents and solutions 
All reagents and solvents used in the radiolabeling syntheses were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated and were 
used as supplied. Absolute ethanol (Etax Aa, 99.6%) was from Altia 
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Corporation (Helsinki, Finland). Buffers and other solutions were prepared 
in ultrapure reverse-osmosis water produced on a Millipore MilliQ system. 
4.1.3 Human plasma 
Human plasma used in the radiolabel stability assays and in vitro studies of 
plasma protein adsorption was anonymous donor FFP 24 plasma obtained 
from the Finnish Red Cross Blood Service (Helsinki, Finland) under ethical 
permissions 55/2008 and 25/2011. The plasma was stored at –20ºC until 
use. 
4.1.4 Trichoderma reesei hydrophobin HFBII
Trichoderma reesei hydrophobin HFBII was produced at the Nanobio­
materials program at the VTT Technical Research Centre of Finland (Espoo,
Finland) using established methods (Linder et al., 2001). HFBII was stored
as a freeze-dried powder at ambient temperature in a desiccator until use.
4.2 RADIOLABELING SYNTHESIS (I–IV)
4.2.1 18F-radiolabeled PSi microparticles 
18F was produced in a 18O(p,n)18F reaction with 10 MeV protons on an IBA 
Cyclone 10/5 cyclotron at the Laboratory of Radiochemistry, University of 
Helsinki. The target was a 2.5-ml H218O enriched water target (>97 %) 
encased in a water-cooled niobium body with a He-cooled 25-!m Ti window.
The helium circuit was isolated from the cyclotron main vacuum with a 
10-!m Ti foil. Radiolabeling synthesis was carried out on a semi-automated 
synthesis unit (DM Automation, Stockholm, Sweden). 18F was separated 
from the target water by solid-phase extraction on a Sep-Pak QMA Light Plus
cartridge (Millipore Corporation) and eluted as 18F–/Kryptofix2.2.2/K+ 
complex to a 5-ml conical Alltech Mini-Vial™. The complex was dried with 
azeotropic distillation at +120ºC under a 45 ml min–1 argon or N2 flow. The 
vial was cooled to room temperature with pressurized air, and the residue 
was dissolved in 400 !l of the designated solvent (DMF, DMSO, or aceto­
nitrile) and added to 0.3–1.o mg of dry PSi particles suspended in 
approximately 100 !l of the solvent in a 5-ml Mini-Vial™. Approximately 
100 MBq of 18F–/Kryptofix2.2.2/K+ was used for radiolabeling of 1 mg of 
particles. In selected radiosyntheses, acetic acid was added to a final 
concentration of 4% (v/v) to the reaction mixture. The vial vas placed on a 
preheated mantle on the synthesis unit and heated for 10 minutes. 
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The microparticles were purified from the reaction mixture by sequential 
washes in DMF, absolute ethanol, 1"PBS (pH=7.4), and ultrapure water 
according to the procedure described in original publication I. The particles 
were collected from the solutions by filtration through a 0.1-!m PTFE 
membrane (Omnipore, Millipore Corporation). The washing step in 1"PBS 
(pH=7.4) was extended to include a 20-minute incubation at room 
temperature in order to release free 18F radiolabel from the porous network.
Radioactivity of both the filter and filtrate together with the residual radio­
activites retained on both were measured on a dose calibrator (CRC-210, 
Capintec Inc.) and decay-corrected to the start of synthesis. The decay-
corrected values were used to calculate the radiochemical yield (RCY) as 
described in section 4.3.1. 
4.2.2 	 Radiosynthesis of [18F]THCPSi nanoparticles for biodistribution 
studies 
[18F]THCPSi nanoparticles were synthesized essentially as described above 
for the microparticles. Briefly, 0.5–1.0 GBq of the dried 18F–/Kryptofix2.2.2/ 
K+ complex was dissolved in 500 !l of DMF with 4% (v/v) of acetic acid and 
added to 1 mg of THCPSi nanoparticles. The mixture was heated at +120°C 
for 15 minutes, and the nanoparticles purified with the sequential centri­
fugation protocol outlined in original publication II. Final formulations were 
prepared in 5% Solutol–1#HBSS (pH 7.4). 
4.2.3 	 Radiosynthesis of [18F]NaF for biodistribution studies
[18F]NaF was prepared from the 18F in the target water by passing the entire 
target volume through a Chromafix 30-PS-HCO3 cartridge (Macherey Nagel)
and eluting with 0.9% NaCl. The eluate was diluted to the desired volume 
with the vehicle (I–IV).
4.2.4 	 125I-radiolabeled HFBII 
In studies III and IV, radioiodination of HFBII to yield [125I]HFBII was 
carried out using the Bolton-Hunter method (Bolton et al., 1973) with SHPP 
(N-succinimidyl-3-(hydroxyphenyl)propionate) synthesized from 3­
(4-hydroxyphenyl)propionic acid and N-hydrosuccinimide as described 
previously (Li et al., 2006). Purity of SHPP was confirmed with 1H-NMR.
SHPP was radiolabeled with 125I in 10 !M NaOH (pH=8–10, reductant-free,
PerkinElmer Inc.) and the purity of [125I]SHPP checked with TLC on a Merck 
Kieselgel 60 F254 plate developed with 9:1 (v/v) ethyl acetate–methanol and 
analyzed with digital autoradiography. The synthesized [125I]SHPP was 
subsequently dried under a nitrogen flow and 50 !l of 1 mg ml–1 solution of 
HFBII in 100 mM sodium borate buffer (pH=8.5) added to the residue. The 
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reaction mixture was incubated at +40°C for 45 minutes. [125I]HFBII was 
purified with size exclusion chromatography on a PD MiniTrap G-25 column 
(GE Healthcare) preconditioned with 8 ml of McIlvaine buffer, pH=4.0 
(0.2 M NaHPO4—0.1 M citrate (McIlvaine, 1921)). The product was eluted 
with 3 mL of the buffer collecting 200-!l fractions. The fractions were 
measured on a dose calibrator, and the peak fractions pooled. Radiochemical 
purity of [125I]HFBII was checked with paper chromatography on a 
Whatman 1 filter paper (Millipore Corporation) developed with 50:50 (v/v) 
methanol–H2O, and analyzed with digital autoradiography. The Rf values
were 0.0 for [125I]HFBII, and 1.0 for free [125I]I–. 
Immediately after pooling, the [125I]HFBII was supplemented with 0.1 mg of 
HFBII carrier in order to prevent adsorption to the vial walls. HFBII in the 
final product was quantified with liquid chromatography against a standard 
series on a Shimadzu Prominence UFLC system consisting of two LC-20AD 
pumps, SIL-20AHT autosampler, CTO-20AC column oven, SPD-20A UV/vis 
detector (!=205 nm), and an external NaI scintillation crystal radiodetector 
operated at +0.90 kV. Separation was carried out on an Agilent Zorbax 
Eclipse XDB-C8 column (4.6 # 150 mm, 3.5 !m particle size, Agilent 
Corporation) in 80:20 0.1% trifluoroacetic acid (TFA) in H2O—0.08% TFA in 
acetonitrile at 2.5 ml min–1. A linear gradient of 0.08% TFA in acetonitrile to 
60% was applied over 7 minutes.
4.2.5 	 Post-radiosynthetic functionalization of [18F]THCPSi 
nanoparticles with HFBII (III & IV) 
In studies III and IV, HFBII-functionalized [18F]THCPSi nanoparticles 
(HFBII-[18F]THCPSi) were produced by coating the freshly radiolabeled 
nanoparticles with the protein. 0.24–0.67 GBq of the [18F]THCPSi nano­
particles in ethanolic solution were added slowly to a 4.0±0.1 mg ml–1 
solution of HFBII in McIlvaine buffer, pH=4.0. The mixture was shaken
gently and incubated at +80°C on the preheated mantle of the synthesis unit 
for 30 minutes. The particles were separated from the solution by centri­
fugation at 15,000g for 10 minutes and washed with 3#1 ml of ultrapure 
water.
4.3	 CHARACTERIZATION OF RADIOLABELED
PARTICLES AND FREE-STANDING FILMS (I–IV)
4.3.1 	 Radiochemical yield 
The radiochemical yield (RCY) from the activated 18F–/Kryptofix 2.2.2/K+ 
complex was calculated from the decay-corrected radioactivity in the final 
particle product. Particle loss in the purification steps (e.g. residual activity 
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on the reaction vial, filters or centrifuge tubes) was accounted for in the 
calculation. 
4.3.2 Specific radioactivity 
Specific radioactivity (SA) was determined for each synthesized batch of 
18F-radiolabeled PSi particles used in studies II–III. For SA determination,
nanoparticles from a 0.1-ml aliquot of the formulated solution were washed 
with 3#1 ml of ultrapure water, freeze-dried overnight, and weighed.
4.3.3 Zeta potential 
Zeta potentials were measured in ultrapure water on a ZetaSizer Nano 
instrument (Malvern Ltd.) in a disposable polycarbonate capillary cell at 
+25°C. The zeta potential was calculated from the nanoparticle eletro­
phoretic mobility using the Smoluchowski relation.
4.3.4 Particle size 
Nanoparticle size distributions were obtained from dynamic light scattering 
(DLS) measurement data on the ZetaSizer Nano instrument. Measurements 
were conducted either in 0.09% NaCl or ultrapure water at +25°C in a 
disposable polycarbonate cell. In addition, transmission electron microscopy 
(TEM) was used to estimate the size distribution of [18F]THCPSi nano­
particles synthesized in original publication II.
4.3.5 Spectroscopy
The spectroscopic studies in publication I were carried out at the Laboratory 
of Industrial Physics, Department of Physics and Astronomy, University of 
Turku.
4.3.5.1 FTIR 
Fourier-transform infrared spectroscopy (FTIR) was performed on free­
standing PSi films radiolabeled in the carrier-added (0.172 mmol 19F) 
conditions. Transmission and attenuated total reflectance (ATR) spectra 
were measured on a Spectrum BX spectrometer (PerkinElmer Inc.) using a 
scan range from 4000 to 550 cm–1 with a resolution of 4 cm–1, averaging 32 
scans. The ATR accessory used was a single-reflection MIRacleATR (Pike 
Technologies Inc.) equipped with a diamond crystal. Spectra for 
18F/19F-THCPSi films was obtained in the transmission mode, whereas 
spectra for 18F/19F-TOPSi and 18F/19F-TCPSi were obtained with ATR-FTIR 
mode due to the high IR absorbance of the films below 1200 cm–1. 
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4.3.5.2 XPS 
XPS measurements of 18F/19F-radiolabeled THCPSi, TOPSi, and TCPSi 
microparticles were carried out on a PHI 5400 ESCA spectrometer 
(PerkinElmer) with a monochromated Mg K! X-ray source (h" = 1253.6 eV) 
using a 45° take-off angle and 35.75 eV pass energy. The microparticles were 
adhered to a double-sided carbon tape and placed into a vacuum of less than 
10–8 mbar. The spectra were charge-corrected by calibrating the binding 
energy of lattice silicon Si (2p) peak to 99.4 eV. 
4.3.6 HFBII content 
The amount of HFBII adsorbed onto HFBII-coated nanoparticles was 
determined by dissolution of the protein coating from a known amount of 
nanoparticles in 2.5% (w/v) SDS—0.5% (v/v) ethanol at ambient 
temperature for 48 hours. Dissoluted HFBII in the solution was quantified 
using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions.
4.4 STABILITY TESTS (I, III–IV)
4.4.1 Stability of the 18F-radiolabel
In study I, stability of the 18F-radiolabel was investigated by incubating the 
radiolabeled PSi microparticles in the conditions given in Table 4. Freshly 
synthesized 18F-radiolabeled PSi microparticles were suspended in ultrapure 
water and added to the respective solutions in 15-mL conical polypropylene 
centrifuge tubes (BD Falcon) using 400 !l of microparticle suspension to 
4 ml of the incubation. The samples were mixed with shaking and incubated 
for 15, 30, 60, 120, 180, and 240 minutes. At each time point, the particles 
were filtered out from the incubation with a 0.45-!m hydrophilic mixed 
cellulose ester membrane (HA, Millipore Corporation) and washed once with 
4 ml of either the buffer under study, or 1#PBS in the case of plasma and the 
simulated fluids. Both the filtrate and the filter were subsequently measured 
on a dose calibrator to determine the amount of radioactivity retained on the 
particles. 
4.4.2 Stability of the HFBII coating 
[125I]HFBII (section 4.2.2) was used in studies III and IV to assess the 
stability of the protein coating in the conditions presented in Table 4. In
short, THCPSi nanoparticles were coated as described in section 4.2.3, but 
the coating solution was spiked with 0.05–0.2 MBq of [125I]HFBII. A 1:4 
(w/w) ratio of nanoparticles to HFBII was maintained in the coating 
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Materials and methods
procedure. Freshly prepared [125I]HFBII-coated THCPSi nanoparticles were 
suspended in 100 !l of 1#PBS and added to 5 ml of the medium in conical 
polypropylene centrifuge tubes. At designated time points, samples of 200 !l 
were drawn from the incubation, and the nanoparticles were separated by 
centrifugation at 15,000g for 10 minutes. Radioactivity of the nanoparticle 
pellets and supernatants was measured on an automated gamma counter
(Wizard3, PerkinElmer) for 10 minutes. In order to identify the radioactive 
species in the supernatant (i.e. [125I]HFBII vs. [125I]I–), a 1-!l sample from all 
supernatants was analyzed with paper chromatography and digital 
autoradiography as described in section 4.2.2.
Condition pH Buffer Temperature Agitation Study
"C rpm
 
18F-radiolabel 
 "stomach pH" 2.33 H3PO4 22 Istability
 
"physiological
 7.41 NaH2PO4 22 IpH"
 
"duodenal peak 
 8.7 Tris-HCl 22 IpH"
Human plasma n/a 37 200 I
sGF 1.2 37 200 I
FaSSIF 6.5 37 200 I
[125I]HFBII 1xPBS 7.4 22 IVcoating stability
Human plasma n/a 37 IV
sGF 1.2 37 III
FaSSIF 6.5 37 III
n/a: not determined
Table 4. The conditions used for the radiolabel stability tests in studies I and 
III–IV.
4.5 IN VITRO STUDIES IN CELL CULTURE (II–IV)
The in vitro evaluation of the nanoparticles described in the present work
was conducted at the Division of Pharmaceutical Technology, Faculty of 
Pharmacy, University of Helsinki, Finland.
4.5.1 Biocompatibility 
Biocompatibility of THCPSi and HFBII-THCPSi nanoparticles was
investigated in several cell lines (Table 5) relevant to systemic and oral 
administration. The cells were maintained as described in the respective 
original publications II–IV. The biocompatibility of the nanoparticles was 
assessed in terms of cell viability, intracellular ROS production,
inflammatory response, cell morphology, and association with the particles.
The respective assays are described in the original publications II–IV.
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Cell line Source Assays Study
Caco-2 Human colon carcinoma V, O, P II
RAW 264.7 Murine leukemic monocyte macrophage V, O, Inf, Int II,IV
AGS Human adenocarcinoma V, M III
HepG2 Human hepatocellular carcinoma V IV
V, cell viability; O, oxidative stress; P, permeation; Inf, inflammatory response
Int, nanoparticle internalization; M, mucoadhesion
Table 5. The cell lines used for the biocompatibility studies in publications II–IV.
4.5.2 Mucoadhesion 
In vitro mucoadhesion of HFBII-THCPSi nanoparticles to AGS cells was 
investigated in study III. For the mucoadhesion assay, the cells were
maintained as described in the original article, and seeded to a density of 
1.5#105 cells/well on a 12-well plate (Corning Life Sciences), either directly on 
the bottom of the well or on a 13-mm glass coverslip, and allowed to attach 
overnight. The cells were washed twice with 1#HBSS, pH=7.4, and 
subsequently 500 !L of [125I]HFBII-THCPSi nanoparticle solution (19.3 kBq 
mL–1 in 1#HBSS) was added. The cells were incubated with the nanoparticles 
for 15, 30, 60, 120, 180, and 240 minutes. At each time point, the cells grown 
directly on the well were washed once with 1 ml of 1#HBSS, and detached 
with 1 mL of 0.25% (v/v) trypsin–EDTA–PBS, and the radioactivity retained 
in both the cells and the media were measured on an automated gamma 
counter for 10 minutes. For microscopic and autoradiographic investigations,
the cells grown on coverslips were stained with CellMask™ (Molecular 
Probes, Invitrogen) for 5 minutes in 1 mL of 15 !g ml–1 solution, and fixed 
with 2% glutaraldehyde in 0.1 M phosphate buffer, pH=7.4 for 30 minutes.
The coverslips were washed with 1#HBSS and allowed to dry at room 
temperature. The coverslips were mounted in Vectashield™ (Vector 
Laboratories) and sealed to a microscope slide using clear nail polish. The 
slides were subsequently exposed to a digital imaging plate (SR2040,
Fujifilm Corporation) for 72 hours. The imaging plate was scanned on a 
Fujifilm FLA-5100 scanner in the IP-S mode at a nominal resolution of 10 
!m. The digital autoradiographs were analyzed with AIDA 2.0 imaging 
software (Raytest Isotopenmessgeräte GmbH). Finally, the slides were 
examined under an Olympus IX71 inverted fluorescence microscope for cell 
morphology. 
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Materials and methods
4.6 BIODISTRIBUTION STUDIES (I–IV)
4.6.1 Animal husbandry 
All experimental procedures were approved by the national board for animal 
experimentation in Finland (State Provincial Office of Southern Finland,
Hämeenlinna) with license numbers ESLH-2008-10652/Ym-23 and ESLH­
2009-02146/Ym-23. Male Wistar:Han rats (200–300 g, age 8–12 weeks) 
were obtained either from Harlan (Horst, the Netherlands) or from the in­
house breeding program at the Laboratory Animal Centre of University of 
Helsinki. Upon receipt, the animals were allowed to acclimatize to the 
environmental conditions at the animal facility for 2–5 days. The animals
were gently handled daily during the acclimatization period to familiarize 
them with the researcher and administration procedures. The rats were 
housed in groups of 2–3 in raised 265"180"420 mm polycarbonate cages
(Ehret GmbH, Emmendingen, Germany) on aspen bedding (Tapvei Oy,
Kaavi, Finland) in a HEPA-filtered air flow cabinet operated at negative 
pressure (Uniprotect, Ehret GmbH). The temperature in the cabinet was set 
to 21±1°C. Relative humidity of 55±10% was maintained with an ultrasonic 
humidifier. Food (Harlan Teklad Global Diet 2018) and tap water were 
available ad libitum. The cages were supplied with aspen shavings, aspen 
gnawing sticks (both from Tapvei), and egg cartons (recycled pulp) to 
provide enrichment and nesting material for the animals. The lighting in the 
animal facility was set to 12:12 rhythm (lights on from 07:00 to 19:00). The 
experiments were carried out during the light phase. 
4.6.2 Fasting 
Liquid fasting of the animals was used in studies II to IV in order to clear the 
GI tract of digestive matter before administration of the radiolabeled 
nanoparticles. The animals were transferred to single housing and the food 
was withheld for a minimum of 12 hours prior to administration starting 
from the evening before the experimental day. All enrichment material 
except for the bedding and a small swatch of aspen shavings were removed to 
discourage pica (the consumption of non-food items) during fasting. Animals 
had free access to freshly prepared 10% (w/v) glucose solution during the 
fasting period and until the end of the experiment.
4.6.3 Administration of 18F-radiolabeled PSi particles 
Three administration routes were used in the animal experiments in studies I
to IV, namely intragastric gavage for oral administration, and subcutaneous 
and intravenous injections for parenteral administration. Intragastric gavage 
was performed with a 2-ml syringe fitted with a silicone-tipped single-use 
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18G feeding needle (AgnTho’s, Lidingö, Sweden). The feeding needle was 
moistened with 20% glucose solution and passed down the esophagus of the 
animal held by a neck scruff. The syringe contents were gently expelled into 
the stomach and the needle withdrawn. Administered volume was 1 ml. The 
respiration of the rat was checked immediately after administration for 
gargling sounds to rule out aspiration to the trachea, before returning the 
animal to its cage. Subcutaneous injections were given under the skin fold in 
the neck in a volume of 150 !l with a 25G needle. For intravenous 
administration, the rats were anesthetized with isoflurane (IsoFlo Vet, Orion 
Pharma, Espoo, Finland) in 100% O2 carrier. Anesthesia was induced at 4.5% 
isoflurane concentration at a flow rate of 4 l min–1 and maintained with 
1.5–3% isoflurane at 2.5 l min–1. One of the lateral tail veins was cannulated 
under anesthesia with a temporary 24G infusion catheter (BD Neoflon™, BD 
Medical Surgical Systems) and the patency of the catheter checked with 
injection of 70 !l of sterile 0.9% NaCl. In order to prevent the passage of 
blood to the radiotracer syringe, the catheter was capped with a closed Luer 
valve (BD Q-Syte™) to which the radiotracer was administered. The valve 
and catheter were flushed with 150 !l of sterile 0.9% NaCl after administra­
tion, allowed to remain in place for 30 seconds and removed. The supply of 
isoflurane was cut off immediately after administration in order to speed up 
recovery from the anesthesia. The tail was elevated and pressure was applied 
to the wound to stop bleeding during the recovery period before returning 
the animal to its cage.
4.6.4 Biodistribution
At designated time points after administration, the rats were sacrificed with 
CO2 asphyxiation followed by cervical dislocation. Immediately after 
confirmation of the death of the animal by the disappearance of the corneal 
reflex, the thorax was opened and a 1-ml blood sample drawn from the left
chamber of the heart with a 22G needle. Samples were dissected from the 
gut-associated lymphoid tissue (GALT), spleen, liver, kidney, testis, stomach,
lung, heart, brain and bone (from the parietal bone in the skull). Sample for
urine was drawn directly from the urinary bladder. For animals dosed with 
intragastric gavage, a segment of the esophagus was excised, as was 
approximately 1.5 cm long segment of the tail around the injection site for 
intravenously dosed animals. These samples were included to verify success 
with the administration. All tissue samples were rinsed with 1"PBS (pH=7.4) 
and blotted dry on tissue paper. The samples were transferred to 5-ml 
polyethylene tubes, weighed, and their radioactivity counted in an automated 
gamma counter (Wizard3, PerkinElmer Inc.) for 60 seconds with three
repeats for each sample. 
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Materials and methods
4.7 EX VIVO AUTORADIOGRAPHY (II & III)
4.7.1 Macroautoradiography (II & III) 
Nanoparticle distribution in the lower GI tract was analyzed with macro-
autoradiography. After sacrifice, the whole lower GI tract of the animal was 
dissected from the pyloric spinchter and the rectum, rinsed with 1"PBS 
(pH=7.4), blotted dry on a tissue paper and arranged on a transparency. The 
sample was photographed for subsequent gross anatomical identification of 
the GI tract segments. The transparency was wrapped in household-brand 
cling film and transferred on top of a SR2040 digital imaging plate (Fujifilm) 
in an autoradiography cassette. The imaging plate was exposed for 5, 10, 20, 
or 30 minutes for animals sacrificed at 1 h, 2 h, 4 h, and 6 h after administra­
tion, respectively. The imaging plate was scanned on a Fujifilm FLA-5100
scanner in the IP-S mode at nominal resolution of 25 !m. Autoradiographs 
were subsequently analyzed with Aida 2.0 imaging software (Raytest
Isotopenmessgeräte GmbH). Regions of interest (ROIs) were drawn on the 
autoradiograph based on the identification of the segments in the photo­
graph.
Additionally, selected animals that were subcutaneously injected with 
[18F]THCPSi nanoparticles or [18F]NaF in study II were imaged with whole-
body macroautoradiography by exposing the entire carcass to the digital 
imaging plate. The euthanized animal was placed on a supine position on the 
imaging plate for 20 seconds. The plate was processed as described above. 
4.7.2 Cryosection autoradiography (III) 
In study III, cryosection autoradiography was used to study the adhesion of 
HFBII-[18F]THCPSi nanoparticles to rat stomach and ileum after oral 
administration. The stomach was dissected from the esophageal junction and 
pyloric spinchter. A 2.5-cm segment of distal ileum was cut cranially from the 
cecal junction. The samples were rinsed gently of chyme and fecal matter
with 1"PBS (pH=7.4) administered via a blunt needle. Care was taken to 
avoid abrasion of the mucosal membrane with the needle tip. The lumen of 
the sample was rinsed once more with 4% NBF (neutral buffered formalin)
and filled with additional 4% NBF. The samples were pinned closing the 
openings to 5-mm thick cork plates and fixed in 4% NBF for 30 minutes in 
order to prevent the tissue from everting. After fixation, NBF was gently 
squeezed out from the lumen, and the specimens were dilated with Jung 
tissue freezing medium (Leica Microsystems) and snap-frozen in isopentane 
over dry ice. After freezing, the stomach was cut in half at the level of the 
cardia to separate the forestomach and the glandular stomach. 
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The samples were cut to 25-!m thick coronal sections on a cryostat micro­
tome (Leica CM1950) at –12°C and thaw-mounted on SuperFrost Plus glass 
slides (VWR Collection). The sections were allowed to dry at room 
temperature, arranged to an autoradiography cassette, and exposed to a
TR2040 digital imaging plate (Fujifilm) for 12 hours. The imaging plate was 
scanned as described above with nominal resolution of 10 !m. The sections 
were subsequently stained with hematoxylin–eosin (H&E), mounted in DPX,
and imaged under an Axioplan 2 microscope fitted with Axiocam HRc 
camera and AxioVision 3.2 software (all from Carl Zeiss Microimaging 
GmbH).
4.8 IN VITRO PLASMA PROTEIN ADSORPTION (IV)
Both THCPSi and HFBII-THCPSi nanoparticles (90 !g each) were suspended 
in 1 mL of human plasma in 1.5-ml polypropylene centrifuge tubes (Protein 
LoBind™, Eppendorf GmbH) and incubated at +37ºC. At 15, 60, and 120
minutes of incubation, the particles were collected by centrifugation and 
washed twice with 1 ml of ultrapure water. Washed particles were re­
suspended in ultrapure water and the particle size and $-potential measured 
as described above. Size distribution peak analysis was carried out using a
multiple Gaussian peak fit in Origin software (version 7.5, OriginLab 
Corporation) to yield the average size for free and aggregated nanoparticle 
fractions. 
For identification of the adsorbed plasma proteins after 120 minutes of 
incubation, the proteins were extracted from the nanoparticles with 15 !l of 
SDS-PAGE sample buffer (125 mM Tris-HCl, pH=6.8, 2% SDS, 5% glycerol,
and 0.002% bromophenol blue) at +100°C for 5 minutes. The samples were 
run on a 9% SDS-PAGE gel for 2.5 h at a constant voltage of 100 V. The gel 
was stained with Coomassie brilliant blue (Thermo Fisher Scientific) and the 
major protein bands were excised and digested in-gel with sequencing grade 
modified trypsin (Promega Corporation) at +37°C, pH=8, for 16 h. The 
tryptic digests were separated with liquid chromatography and analyzed with 
a QSTAR XL hybrid quadrupole time-of-flight mass spectrometer (Applied 
Biosystems) as described in detail elsewhere. The adsorbed proteins were 
identified from their peptide mass fingerprint data with MASCOT search 
engine (version 1.6b25, script 27, http://www.matrixscience.com). The 
MASCOT searches were carried out against the UniProt database (release 
2011_09, http://www.uniprot.org) that contained 532 146 sequences. Parent 
ion and fragment mass tolerances were 0.1 and 0.2 Da, respectively.
Oxidation of methionine was selected as a variable modification.
55 

   
    
 
 
   
 
Materials and methods
4.9 STATISTICAL METHODS (I–IV)
Where appropriate, statistical analysis of the results was carried out with 
Student’s t-test on PASW Statistics (version 18.0.0, IBM Corporation) or 
GraphPad Prism software (version 5.01, GraphPad Software). P values of 
<0.05 between groups (e.g. [18F]THCPSi vs. [18F]NaF, or HFBII-THCPSi vs.
THCPSi) were considered statistically significant. 
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5 RESULTS 
5.1 18F-RADIOLABELING OF SURFACE-MODIFIED PSi
5.1.1 Radiolabeling synthesis development (I) 
18F-radiolabeling of THCPSi, TCPSi, and TOPSi microparticles was carried 
out using activated nucleophilic 18F-fluoride as a 18F–/Kryptofix 2.2.2/K+ 
complex, either with or without added acetic acid. The most successful 
reaction conditions investigated and the respective decay-corrected RCYs are 
given in Table 6. Because all the steps aside the elution and azeotropic 
distillation of the 18F–/Kryptofix 2.2.2/K+ complex and the heating of the 
microparticle reaction mixture were performed by hand, the duration of the 
radiolabeling synthesis from the EOB to the finished product was set by the 
pace in which the radiochemist operated and leveled to approximately 60 
minutes (Table 6). 
18F-radiolabeling at RCYs ranging from 50–83% in the best conditions for 
each surface-modified PSi type was achieved. The highest RCYs for 
[18F]THCPSi and [18F]TCPSi were obtained with DMF at temperatures above 
+100°C. For [18F]TOPSi, DMSO yielded equally good results. On the 
contrary, acetonitrile at +50°C failed to produce RCYs higher than 34% for 
any particle type. Heating at temperatures above the boiling point of aceto­
nitrile was not systematically investigated, as sealing the reaction vessels 
after the addition of the dried Kryptofix complex tightly enough in order to 
avoid the evaporation of the solvent was not possible.
Because acetic acid has been proposed to enhance the leaving group ability of 
hydroxy and alkoxy groups in the synthesis of 18F-fluorosilanes (Mu et al.,
2008), its effect on the RCY was investigated. An improvement in the RCY of 
[18F]THCPSi was seen with increasing the reaction temperature from +50°C 
to +100°C in DMF with 4% (v/v) acetic acid, whereas no effect was seen in 
[18F]TOPSi and [18F]TCPSi. Further increment in the temperature to +120°C 
did not improve the RCY for any of the 18F-radiolabeled PSi. Curiously, the 
addition of acetic acid to the reaction mixture to a final concentration of 4% 
(v/v) did not improve the yield of the radiolabeling for any of the materials.
In [18F]THCPSi, the radiolabeling yield was not affected by the addition of 
the acid, in contrast to a decrease in the yield that was observed in both 
[18F]TOPSi and [18F]TCPSi. Notably in [18F]TCPSi a pronounced improve­
ment of the RCY was seen when acetic acid was left out. This suggested that 
in [18F]THCPSi the leaving group in the nucleophilic substitution reaction is 
most likely a silyl hydrogen, whereas in the other two materials this cannot 
be disclosed (Höhne et al., 2009). A substitution of oxygen with fluorine,
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Results
which would be feasible in both TOPSi and TCPSi due to the presence of a 
Si–Ox layer on the microparticle surface, should be promoted by acidic 
conditions because the leaving group ability of oxygen is enhanced. However,
this was not supported by our findings.
Particle Solvent T Acetic acid RCY Total synthesis time a 
"C !l %	 min
[18F]THCPSi	 DMSO 100 20 54
CH3CN 50 20 30
DMF 50 20 40±15
100 20 80±8
120 0 81±2 55.9#61.3
120 20 73±10
[18F]TOPSi	 DMSO 100 20 60
CH3CN 50 20 34
DMF 50 20 35±17
100 20 21±4
120 0 55±5 56.7#58.7
120 20 37±7
[18F]TCPSi	 DMSO 100 20 39
CH3CN 50 20 31
DMF 50 20 39±1
100 20 45±7
120 0 79±3 52.4#55.5
120 20 48±7
Table 6. Decay-corrected RCYs and total synthesis time for selected 18F-radio­
labeling reactions for PSi microparticles. aTotal synthesis time from the end of
bombardment (EOB) consists of elution and drying of the 18F–/Kryptofix2.2.2/K+ 
complex (15 min), reaction (10 min), cooling (5 min), first filtration and elution 
(5 min), incubation in 1#PBS-EtOH (20 min), and second filtration and elution. The 
times given in parentheses are approximate.
Purification of the PSi microparticles after the radiolabeling was carried out 
with sequential filtration. A 20-minute incubation in 1#PBS, pH=7.41 was 
necessary in order to release free 18F– from the porous network. Notably,
marked loss of the radiolabel was seen from [18F]TOPSi during this step,
contributing to observed consistently lower RCYs for the material. Since the 
pore volumes were comparable in all of the materials, this suggests that the 
released 18F is detached from the [18F]TOPSi surface, and not the porous 
18F–network. All microparticle preparations were void of free after the 
purification steps (I, Supporting Fig. S1).
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5.1.2 Mechanism of the radiolabeling reaction (I) 
18F–The mechanism of the  incorporation to THCPSi, TCPSi, and TOPSi 
surfaces was elucidated from spectroscopic analysis of the respective PSi 
microparticles and free-standing films. These were radiolabeled under 
carrier-added conditions (0.172 mmol 19F) in order to obtain detectable 
concentration of non-radioactive fluorine atoms on the surface for the FTIR 
and XPS studies. Elemental analysis of the 18F/19F-radiolabeled PSi micro-
particles can be found in Table S1 of Supporting material for original 
publication I. An anticipated increase in the signal for fluorine (F 1s) was 
seen in both THCPSi and TCPSi, corresponding to an increase from 0.39 to 
1.15, and from 0.36 to 0.42 mass-%, respectively. This is possibly a result of 
saturation on the available fluorination sites on the surface, because in the 
carrier-added radiolabeling conditions a 30,000-fold excess of fluorine 
compared to the no-carrier-added conditions is used. In TOPSi, however, no 
increase in the fluorine content was observed. The relatively high initial 
amount of fluorine on the material (0.66 mass-%) suggests that residual silyl 
fluoride groups from the electrochemical etch might be present in TOPSi,
which in turn would promote an isotopic exchange of Si–19F for Si–18F in the 
radiolabeling reaction. In this case one would not expect to find a change in 
the fluorine content after carrier-added radiolabeling. The Si (2p) signals
(Figure 5a) for all the materials showed an increase in the intensity of the 
Si–O peak relative to the Si–Si peak, alluding to possible oxidation of the
immediate surface layers during the radiolabeling reaction. This effect was 
pronounced in TOPSi, and only slight in both THCPSi and TCPSi, where the 
carbonization and hydrocarbonization treatments are likely to have stabilized 
the surface towards oxidation.
The FTIR spectra for the free-standing PSi films after the carrier-added 
radiolabeling are given in Figure 5b. In THCPSi, the CHx stretching 
vibrations at 2900 cm–1 and the vibrations between 1200 cm–1 and 1500 cm–1 
for various alkyl structures characteristic for the material remain unchanged,
indicating that the overall surface chemistry is not altered in the radio­
labeling reaction. In TCPSi small peaks related to CHx stretching were 
detected after the radiolabeling, but these can be accounted for by residual 
DMF in the sample. In TOPSi, however, more dramatic changes were seen 
with the disappearance of the back-bond oxidized OxSi–Hx stretching bands 
(from 2150 cm–1 to 2300 cm–1) and their corresponding deformation modes 
at 870 cm–1. Furthermore, features related to oxidation such as the 
symmetric Si–O–Si stretching vibrations at 800 cm–1 were strengthened in 
TOPSi, much in line with the resuts from the XPS analysis. The possible Si–F 
vibrations are difficult to assign in the FTIR spectra of any of the materials,
because the characteristic peaks reside at lower wavenumbers and the strong 
Si–O related features in the spectra mask the Si–Fx vibrations at 972 cm–1. 
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Figure 5. a) The XPS spectra of the PSi materials before and after carrier-added 
18F-radiolabeling. b) The FTIR spectra for the respective materials. The spectra are
baseline-corrected and shifted vertically for clarity. Adapted with permission from
Sarparanta M et al., Mol Pharmaceutics, 2011, 8(5): 1799–1806. Copyright © 2011 
American Chemical Society.
Based on the results of the spectroscopic studies, the following mechanisms 
for the incorporation of 18F were elucidated (Figure 6). In [18F]THCPSi, the 
radiolabeling reaction is most plausible to proceed via a direct substitution of 
18F– to a silyl hydrogen. In [18F]TCPSi, the incorporation of 18F– is more likely 
to occur by an attack of the nuclophile to the Si–O–Si bridges on the thin 
silicon oxide layer on the Six–Cy surface. In addition to the attack to both a 
silyl hydrogen or to a Si–O–Si bridge, the isotopic exchange of 18F for the 
residual silyl hydrogen is possible in [18F]TOPSi. Nevertheless, it is feasible 
that in all the materials a Si–18F bond is created. 
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Figure 6. Plausible mechanisms for 18F incorporation to PSi surfaces. Reprinted 
with permission from Sarparanta M et al., Mol Pharmaceutics, 2011, 8(5): 1799– 
1806. Copyright © 2011 American Chemical Society.
5.1.3 Radiolabel stability (I) 
Hydrolytic stability of the 18F-radiolabel in [18F]THCPSi, [18F]TOPSi, and 
[18F]TCPSi was investigated in 10 mM buffers covering a physiologically 
relevant pH range from 2.33 to 8.70. In addition, the stability was 
determined in more complex simulated gastric (sGF) and fasted-state 
intestinal fluids (FaSSIF), and in human plasma at +37°C in order to better
predict radiolabel stability in vivo after enteral and parenteral administra­
tion. [18F]THCPSi and [18F]TCPSi showed excellent (>90% of the 18F-radio­
label particle-bound) pH stability for up to 4 hours (I, Figures 2a and 2c),
whereas the stability of [18F]TOPSi declined to 80% and below at pH values 
exceeding 7.41 (I, Figure 2b). All the 18F-labeled particles exhibited high 
stability in the simulated fluids with #90% of the radiolabel retained on the 
particles even at the last time point (Figure 7a–c), indicating that they all 
could be used as nanoparticle tracers after oral administration. Additionally,
the plasma stability of [18F]THCPSi and [18F]TCPSi was sufficiently high to 
allow for their intravenous delivery. The instability of [18F]TOPSi (Figure 
7b), however, was further augmented in plasma likely because of the 
61 

  
 
 
 
 
     
   
     
  
 
 
 
 
 
 
Results
degradation of the material itself at pH > 7, suggesting that [18F]TOPSi might 
not be optimal for intravenous use.
Figure 7. Stability of the 18F-radiolabel in simulated gastric fluid (sGF), in fasted-
state simulated intestinal fluid (FaSSIF), and in human plasma at +37°C for
[18F]THCPSi (a), [18F]TOPSi (b), and [18F]TCPSi (c). Reprinted with permission from
Sarparanta M et al., Mol Pharmaceutics, 2011, 8(5): 1799–1806. Copyright © 2011 
American Chemical Society.
5.1.4 	 Radiolabeling and characterization of [18F]THCPSi nanoparticles 
for biodistribution studies (II–IV) 
Characterization data for the 18F-radiolabeled nanoparticles synthesized in 
studies II–IV is collected in Table 7. The particle size was determined from 
DLS measurements except in Study II, where the size distribution of 
[18F]THCPSi nanoparticles was estimated from TEM images. The results of 
the size distribution analysis verified that the size of the [18F]THCPSi 
nanoparticles was comparable to their non-radiolabeled counterparts (II, 
Figures 1a & 1c). Furthermore, the TEM images showed that the 
nanoparticle morphology was not influenced by the radiolabeling. The
specific radioactivity of the synthesized 18F-radiolabeled particles is under­
standably lower than that of conventional small molecule radiotracers, as 
milligram quantities of the nanoparticles are used in the radiosynthesis to 
ensure recovery of the radiolabeled product.
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Specific Particle Zeta HFBII 
Tracer radioactivity size potential content Study
[18F]THCPSi
MBq/mg
207±139
nm
148–185a 
mV
-30
weight-%
II
HFBII-[18F]THCPSi
HFBII-[18F]THCPSi
203.7±127
73.4±13.9
243.1±40.9b 
324±53b 
-12.75
-21.25
9.5±0.78
8±0.5
III
IV
aDetermined from TEM, bDetermined from DLS
Table 7. Characterization data for the 18F-radiolabeled PSi particles used in the 
biodistribution studies II–IV.
5.2	 BIOCOMPATIBILITY AND CELLULAR ASSOCIATION
OF THCPSi (II)
The in vitro cytotoxic, oxidative, and inflammatory responses to THCPSi 
particles as a function of particle size (from 97 nm to 25 !m) and 
concentration (15–250 !g/ml) were evaluated in Caco-2 and RAW 264.7 cells
after 24 hours of incubation. The cell lines were chosen to simulate cellular 
interactions of the particles on both enteral (Caco-2) and parenteral (RAW 
264.7) administration routes. In Caco-2, the micron-sized particle fractions 
were found to reduce the cell viability more than the nanoparticles, whereas 
in the RAW macrophages an intermediate nanoparticle size of 142 nm was 
tolerated the best (II, Figure 2a–b). A concentration dependency in the 
cytotoxicity, however, could be established for some but not all of the size 
fractions. Intracellular ROS production was comparable in both of the cell 
lines, and significantly lower than the oxidative stress response elicited by 
H2O2, which was used as a positive control (II, Figure 2c–d), suggesting 
that the mechanism underlying the observed cytotoxicity is other than 
oxidative damage. The inflammatory response in RAW 264.7 macrophages 
was assessed from the production of the cytokine tumor necrosis factor !
(TNF-!). The response was lower to nanoparticles with average size of 142 
and 188 nm, corroborating the findings of the cell viability assay (II, Figure
2e). As a conclusion, the THCPSi nanoparticles with the average diameter of 
142 nm were deemed to have the highest biocompatibility, and therefore 
nanoparticles with a comparable size distribution were used in the bio­
distribution studies. Fluorescently labeled THCPSi nanoparticles were used 
to investigate cellular interaction of the nanoparticles in Caco-2 and RAW 
264.7 cells with confocal microscopy. A strong, concentration-dependent 
cellular association of THCPSi nanoparticles was observed (II, Figure
3a–b), but the particles were not extensively internalized in either cell line 
(II, Figure 3c). Permeation of the FITC-labeled nanoparticles across a 
Caco-2 monolayer was minimal (II, Figure 3d).
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5.3	 BIODISTRIBUTION OF [18F]THCPSi
NANOPARTICLES (II)
When evaluated in terms of biocompatibility, RCY, and radiolabel stability in
vitro described in the previous sections, nanosized [18F]THCPSi emerged as 
the first candidate for the in vivo biodistribution studies. The biodistribution 
of [18F]THCPSi nanoparticles was investigated in male Wistar:Han rats via
three routes of nanoparticle administration: oral, intravenous, and sub­
cutaneous. Free 18F– dosed in the form of [18F]NaF in the vehicle served as a 
control for radiolabel stability in vivo. 
5.3.1 Oral 
After oral administration, no permeation of the [18F]THCPSi nanoparticles 
through the intestinal wall was observed, as shown by the biodistribution 
results in II, Figure 4a. Compared to the uptake of orally administered 
[18F]F– in the control animals in organs outside the GI tract (II, Figure 4c),
it can be concluded that the apperance of radioactivity to the bone and urine 
in animals dosed with [18F]THCPSi is due to the release and subsequent
intestinal absorption of the 18F-radiolabel in vivo. The amount of the released
radiolabel, however, corresponded to less than 0.6 %ID/g, further supporting 
the observation on the high radiolabel stability in [18F]THCPSi in vitro
(section 5.1.3). In the macroautoradiographic analysis of the excised lower GI 
tract, the [18F]THCPSi nanoparticles were found to transit through the 
intestines in 4 to 6 hours, after which radioactivity started to appear in fecal 
pellets (II, Figure 5a). In addition, even reappearance of the radioactivity to 
the stomach and proximal small intestine was seen in some animals as a 
result of coprophagy. A somewhat large interindividual variation arising 
from the activities (e.g. coprophagy, pica, rest, drinking) of each animal 
during the experiment was seen in the quantification of the macroautoradio­
graphy results (II, Figure 4b). Nevertheless, a steady passage of the nano­
particles from the proximal to the distal segments of the GI tract was 
observed. In control animals receiving [18F]F– a similar pattern in the transit
can be established (II, Figure 4d), but the radioactivity signal (II, Figure
5b) is more dispersed and traces of fluorine can be seen “clinging” to the 
intestinal wall even at the 4 and 6-hour time points, illustrating absorption of 
18F– from the GI tract. This finding is further supported by the higher 
18F–concentration of in the bone and urine of the control animals (II, 
Figure 4c). 
5.3.2 Intravenous 
After intravenous administration, the nanoparticles were rapidly scavenged 
from the circulation by the liver and spleen (II, Figure 6a). Additionally,
lung accumulation corresponding to 0.40–0.70% ID/g was seen in 30–60 
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minutes. By 4 hours the nanoparticle signal had cleared from the lungs.
Intravenously administered [18F]F– (II, Figure 6c) accumulated to the bone 
and was excreted into urine, illustrating that the radioactivity signal in the 
spleen, liver, and lungs of animals receiving [18F]THCPSi was a result of the 
accumulation of the nanoparticles.
5.3.3 Subcutaneous 
Subcutaneously administered [18F]THCPSi nanoparticles were retained in 
the injection site for the entire duration of the experiment, and unlike [18F]F– 
were not absorbed to the circulation (II, Figure 6b). This was confirmed by 
a post-mortem autoradiography of the backside of the whole animal. 
Furthermore, the dissociation of the 18F-radiolabel from subcutaneously 
administered [18F]THCPSi was minimal, in contrast to the rapid excretion of 
free 18F– into the urine in the control animals (II, Figure 6d).
5.4	 BIOFUNCTIONALIZATION OF [18F]THCPSi WITH
HFBII (III & IV)
5.4.1 Coating of [18F]THCPSi with HFBII 
Post-radiosynthetic functionalization of freshly labeled [18F]THCPSi was 
achieved by coating of the nanoparticles with a self-assembled layer of 
T. reesei HFBII in McIlvaine buffer, pH=4.0, at +80°C. The coating pro­
cedure was adapted to the radiosynthesis scale from a procedure developed 
originally for biofunctionalization of non-radioactive THCPSi microparticles
(Bimbo et al., 2011b). Extension of the duration of the synthesis was 
compensated for by increasing the starting radioactivity for the 18F-radio­
labeling of THCPSi to 1.4–1.8 GBq. Characterization data for the synthesized 
HFBII-[18F]THCPSi nanoparticles is given in Table 7. Successful coating was 
apparent from i) the pronounced change in the wettability of hydrophobic 
[18F]THCPSi (Figure 8), that were dispersed with ease in 0.9% NaCl after
coating with HFBII, and ii) incorporation of 125I-radiolabeled HFBII to the 
particles (see section 5.4.2). Product SA and RCY were retained comparable 
to unmodified [18F]THCPSi (Table 7). 
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Figure 8. Dispersion of HFBII-THCPSi nanoparticles (left) and uncoated THCPSi
(right) in 0.9% NaCl. Reprinted with permission from Sarparanta M et al., Mol
Pharmaceutics, 2012, 9(3): 654–663. Copyright © 2012 American Chemical Society.
5.4.2 Coating stability 
Stability of the HFBII coating was assessed using 125I-radiolabeled HFBII in 
1#PBS (pH=7.4), human plasma, sGF, and FaSSIF. The results are 
summarized in Figure 9. The coating was stable in both 1#PBS and plasma 
(Figure 9a) for up to 240 minutes, suggesting that circulating HFBII-
THCPSi nanoparticles would retain the HFBII biofunctionalization for hours 
after systemic administration rendering the biofunctionalization approach 
feasible for intravenous drug delivery. Likewise, the coating is very stable in 
sGF for 6 hours as depicted in Figure 9b. Curiously, the stability of the 
HFBII coating is dramatically reduced in FaSSIF, as almost 45% of the 
[125I]HFBII is released immediately in the simulated fluid, suggesting that 
the coating could be prone to desorption in the small intestine in vivo.
5.4.3 In vitro biocompatibility of HFBII-THCPSi 
In original publications III and IV, the biocompatibility of HFBII-THCPSi 
was investigated in vitro in cell lines relevant to the oral (AGS cells), and 
intravenous (Hep2G and RAW 264.7 cells) administration routes. In AGS 
cells, a concentration-dependent significant increase in cell viability was 
observed in cells incubated with HFBII-THCPSi after 6 and 24 hours
compared to cells incubated with uncoated THCPSi (III, Figure 2). In RAW 
264.7 macrophages, a similar effect was observed, but only after 12 hours of 
incubation, whereas no change in the cell viability was seen between 
uncoated and coated particles at 3 hours (IV, Figure 2a–b). In the HepG2 
cells no difference in cell viability was observed for either of the nanoparticle 
types (IV, Figure 2c–d). Based on these results it was concluded that 
HFBII-THCPSi nanoparticles were suitable for oral and intravenous delivery.
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Figure 9. Stability of the
[125I]HFBII coating in biological
fluids. Reprinted with permission 
from Sarparanta M et al., Mol 
Pharmaceutics, 2012, 9(3): 654– 
663. Copyright © 2012 American 
Chemical Society.
5.5	 ORAL DELIVERY OF MUCOADHESIVE HFBII-
THCPSi (III)
5.5.1 Mucoadhesion to AGS cells in vitro
Mucoadhesion of HFBII-THCPSi was demonstrated in vitro in AGS cells that 
secrete a mucous layer on the surface in culture. When incubated with 
125I-radiolabeled HFBII-THCPSi nanoparticles, gradual deposition and 
adhesion of the particles to the cells was seen (III, Figure 3). The adhesion 
effect was more pronounced from time points beyond 120 minutes (III, 
Figure 3a–b), suggesting that it takes 30–60 minutes for the nanoparticles 
to come in contact and adhere to the cell layer in the culture. The cells 
appeared morphologically normal with intact plasma membrane and ability 
to secrete mucus (III, Figure 3c). Additionally, clusters of HFBII-THCPSi 
nanoparticles appeared in the brightfield images after 30 minutes and 
increased in numbers for the subsequent time points further corroborating 
the mucoadhesion of the nanoparticles to the cells. The clustering is probably 
due to the lack of agitation during the experiment and does not necessarily 
indicate that HFBII-THCPSi nanoparticles would aggregate in physiological 
conditions. 
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5.5.2 Biodistribution and gastric retention of HFBII-THCPSi 
Quantification of intestinal macroautoradiography for 1–6 hours after 
administration is given in Figure 10. It quickly became evident from the 
macroautoradiography results normalized to the administered dose (in 
PSL/mm2/MBq) that less radioactivity was entering the lower GI tract from 
the stomach of animals dosed with HFBII-[18F]THCPSi compared to animals 
receiving [18F]THCPSi. The effect appeared to persist for the first 3 hours 
after administration, after which the nanoparticles started to behave 
identically. The plausible explanations for this are the loss of mucoadhesion 
for HFBII-[18F]THCPSi with the loss of the coating in vivo as the particles 
leave the stomach together with removal of [18F]THCPSi-associated 
radioactivity from the intestines with the fecal excretion of the nanoparticles 
after 4 hours. As with [18F]THCPSi, only minute amounts of free 18F– released 
from the HFBII-[18F]THCPSi nanoparticles in the GI tract is seen entering 
the circulation (III, Figure 5A). As expected, the HFBII coating further 
stabilizes the Si–18F bond towards hydrolytic or enzymatic cleavage in vivo as 
illustrated by the lower accumulation of released 18F– to bone in animals 
receiving the functionalized nanoparticles (III, Figure 5B). Radioactivity 
measurements of the emptied stomachs of the animals showed that HFBII­
[18F]THCPSi nanoparticles were retained in the stomach for 3 hours after 
administration, whereas [18F]THCPSi were almost completely cleared in 2 
hours (Figure 11).
Further evidence for the mucoadhesion of HFBII-[18F]THCPSi in vivo was 
gained with autoradiographic analysis of cryosections from the stomach and 
ileum. At 2 hours after administration, the bulk of the administered 
radioactivity was found in the lumen of both the forestomach and the 
glandular stomach (Figure 12a). At this point, only little radioactivity had 
reached the ileum. Because the resolution of digital autoradiography with 18F 
does not permit the delineation of the mucosal membrane in the cryosection 
autoradiographs, the sections were subsequently stained with hematoxylin– 
eosin for histological examination (Figure 12b–e). In the forestomach 
(Figure 12b & 12c) only scattered sub-micron nanoparticle aggregates were 
found adhering to the mucosa. The nanoparticle clusters were considerably 
more numerous in the lumen of the sections, where they were found 
associated to the salivated ingested debris, including hair and bedding chips.
Conversely, sheets of HFBII-THCPSi nanoparticles were found in the mucosa 
of the glandular stomach (Figure 12d–e) alluding to strong adhesion that 
could possibly explain the observed delay in the gastric clearance of HFBII-
THCPSi nanoparticles in the in vivo study. Furthermore, as suggested by the 
autoradiography results, no nanoparticles were found in the H&E -stained 
sections of the ileum, hinting that the nanoparticles had lost their 
mucoadhesive properties in the small intestine, and were consequently 
washed away during the staining procedure. 
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Figure 10. a) Distribution of HFBII-[18F]THCPSi and [18F]THCPSi nanoparticles in 
the rat lower GI tract as a function time quantified from macroautoradiography. The 
results are expressed as units of photostimulable luminescence (PSL) per mm2 
normalized to the administered dose of 18F-radiolabeled particles in MBq. Values
represent mean±SD (n=3 per time point), *p < 0.05. (B) Representative macroauto­
radiographs of the rat GI tract at 1–6 h after oral administration of HFBII­
[18F]THCPSi nanoparticles. A schematic diagram on top shows the arrangement of
the intestines in the autoradiography cassette. Reprinted from Biomaterials, 33(11),
Sarparanta M & Bimbo LM et al., The Mucoadhesive and Gastroretentive Properties
of Hydrophobin-Coated Porous Silicon Nanoparticle Oral Drug Delivery Systems,
pp. 3353–3362. Copyright © 2012, with permission from Elsevier.
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Figure 11. Gastric clearance of HFBII-[18F]THCPSi nanoparticles versus uncoated 
[18F]THCPSi nanoparticles. Values denote mean±SD (n = 3 per time point), *p <
0.05. Reprinted from Biomaterials, 33(11), Sarparanta M & Bimbo LM et al., The 
Mucoadhesive and Gastroretentive Properties of Hydrophobin-Coated Porous
Silicon Nanoparticle Oral Drug Delivery Systems, pp. 3353–3362. Copyright ©
2012, with permission from Elsevier.
5.6 INTRAVENOUS DELIVERY OF HFBII-THCPSi (IV)
5.6.1 	 Effects of plasma protein adsorption to particle size and zeta 
potential in vitro 
First evidence for the ability of the HFBII biofunctionalization to modify the 
adsorption of plasma proteins to THCPSi nanoparticles was acquired from 
the changes in the particle size and zeta potential observed after incubation 
of the nanoparticles in human plasma. Already after 15 minutes, uncoated 
THCPSi nanoparticles formed aggregates that could not be broken down 
even by extensive sonication, whereas no aggregation was observed for 
HFBII-THCPSi over the 120 minutes of the experiment (IV, Figure 3a–b).
The average diameter of the THCPSi aggregates increased from 1 !m to a 
final size of 2 !m (IV, Figure 3c). Furthermore, the fraction of non-
aggregated THCPSi particles derived from the DLS measurement data 
declined from 16.9% at 15 minutes to 1.1% at 120 minutes. In contrast, the 
particle size in HFBII-THCPSi increased only slightly between 15 and 120 
minutes. A pronounced increase from -30 to -9 mV was seen in the zeta 
potential of THCPSi after the plasma incubation, but the zeta potential of 
HFBII-THCPSi rose only slightly from -21 to -17 mV, further corroborating 
that the secondary adsorption of plasma proteins was different between the 
two nanoparticle types (IV, Figure 3d).
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5.6.2 Biodistribution 
After intravenous administration the HFBII-[18F]THCPSi nanoparticles 
accumulated to the liver and spleen, but the pattern of nanoparticle 
sequestration to these organs was different from that observed for uncoated 
[18F]THCPSi nanoparticles (Table 8). The functionalization significantly 
altered the liver-to-spleen ratio of nanoparticle uptake, yielding roughly 
equal distribution of the nanoparticles between the two major MPS organs in 
animals dosed with HFBII-[18F]THCPSi. In animals receiving [18F]THCPSi 
the spleen uptake was consistently 2-fold higher than the liver uptake at all 
the time points. In addition, [18F]THCPSi nanoparticles were retained in the 
lung at greater quantities despite their smaller initial particle size, indicating 
that they could aggregate also in vivo resulting in entrapment to the lung 
capillary bed. The HFBII functionalization, however, failed to prolong the 
circulation time of [18F]THCPSi nanoparticles. This suggests that despite the
Figure 12. Autoradiography
and H&E stain of rat stomach 
and ileum (A) and photomicro­
graphs of the H&E–stained 
sections showing forestomach 
(B–C) and glandular stomach 
mucosa (D–E) at 2 h after 
administration of HFBII­
[18F]THCPSi nanoparticles by
intragastric gavage. Scale bar
20 !m. Arrows indicate HFBII­
[18F]THCPSi nanoparticle 
clusters and sheets.
Reprinted from Biomaterials,
33(11), Sarparanta M & Bimbo 
LM et al., The Mucoadhesive 
and Gastroretentive Properties
of Hydrophobin-Coated Porous
Silicon Nanoparticle Oral Drug 
Delivery Systems, pp. 3353­
3362. Copyright © 2012, with 
permission from Elsevier.
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altered plasma protein adsorption, the nanoparticles remain prone to 
immune recognition and rapid removal from the bloodstream by the cells of 
the MPS system. Again, when compared to the biodistribution of free 18F–,
HFBII-[18F]THCPSi nanoparticles displayed an entirely different distribution 
pattern corroborating that the accumulation of radioactivity to the liver and 
spleen is due to the uptake of the nanoparticles. Furthermore, as with 
enterally administered HFBII-[18F]THCPSi, significantly less 18F– is released 
from the nanoparticles and accumulates to bone in vivo (Table 8),
illustrating the protective effect of the coating to the underlying Si–18F bond
also in plasma. 
HFBII-[18F]THCPSi (ID%/g) [18F]THCPSi (ID%/g)
15 min 30 min 60 min 15 min 30 min 60 min
Blood 0.02±0.00 0.03±0.02 0.01±0.01 0.32±0.15 0.45±0.35 0.09±0.05
GALT 0.01±0.00 0.01±0.00 0.02±0.00 0.02±0.01 0.04±0.00 0.04±0.01
Stomach 0.02±0.02 0.01±0.00 0.01±0.00 0.03±0.02 0.12±0.11 0.05±0.05
Liver 7.06±1.27* 10.43±2.98 9.07±3.78 3.90±0.79 6.34±0.83 7.67±1.46
Lung 0.42±0.11* 0.70±0.32 0.55±0.42 2.30±1.58 0.73±0.10 0.40±0.14
Kidney 0.05±0.01 0.05±0.03 0.03±0.02 0.21±0.06 0.35±0.17 0.15±0.08
Spleen 7.28±1.31 8.65±1.70 6.22±3.62 8.61±1.36 14.35±6.21 14.53±5.21
Testis 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.00 0.01±0.00 0.01±0.00
Brain 0.00±0.00 0.01±0.00 0.00±0.00 0.02±0.01 0.03±0.02 0.01±0.01
Bone 0.02±0.00* 0.04±0.01* 0.04±0.02* 0.07±0.01 0.15±0.03 0.21±0.05
Heart 0.02±0.01 0.04±0.01 0.01±0.00 0.47±0.31 0.52±0.52 0.76±1.29
Urine 0.15±0.10 0.21±0.29 0.40±0.47 0.28±0.13 0.55±0.46 0.73±0.44
Liver/spleen 0.99±0.22* 1.20±0.20* 1.56±0.39* 0.45±0.05 0.49±0.19 0.60±0.29
Table 8. Biodistribution of HFBII-[18F]THCPSi and [18F]THCPSi nanoparticles after
intravenous administration. Values represent the average ± SD for 3–4 animals,
*p < 0.05.
5.6.3 Identification of adsorbed plasma proteins 
In order to understand the differential sequestration of the nanoparticles 
between the liver and the spleen observed in the biodistribution study, we 
conducted a proteomic characterization of the plasma protein corona formed
on the respective particles in vitro. The SDS-PAGE separation of the 
components of the protein corona is shown in IV, Figure 4. The identified 
plasma proteins adsorbed to both nanoparticle types are given in Table 9,
and the analyzed bands with their MASCOT scores can be found in Figure 
S3 and Table S1 in the Supporting Information for original publication IV.
The identity of the adsorbed plasma proteins was found to vary considerably 
depending on the surface functionalization. All of the identified proteins have 
been previously implicated in studies on secondary plasma protein 
adsorption to nanoparticles. Out of the hits in this study, only inter-!-trypsin 
inhibitor heavy chain H4, immunoglobulin G (IgG, "-1 and "-2 chain C 
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regions), and apolipoprotein A-I were identified for both THCPSi and HFBII-
THCPSi. Interestingly, abundant plasma protein components typical to the 
early stages of the corona formation including serum albumin (HSA),
fibrinogen, and serotransferrin were found only in THCPSi, whereas 
complement C3, IgM, apolipoproteins E and A-IV, and clusterin (apo­
lipoprotein J) were found only in HFBII-THCPSi. With the exception of IgG 
and fibrinogen, all the identified proteins have a pI value that renders them a 
negative or neutral charge at physiological pH. Additionally, both nano­
particle samples were devoid of certain proteins found in the control plasma,
namely !-2-macroglobulin, hemopexin, and apolipoprotein B-100, 
suggesting that these had not been adsorbed in detectable quantities.
Protein Nominal MW pIa THCPSi HFBII-THCPSi
Da
Apolipoprotein B-100 515283 6.57 - -
Complement C3 187030 6.02 - +
!-2-macroglobulin 163188 6.03 - -
Inter-!-trypsin inhibitor heavy chain H4 103293 6.51 + +
Fibrinogen ! chain 94914 5.7 + -
Serotransferrin 77014 6.81 + -
Serum albumin 69321 5.92 + -
Fibrinogen " chain 55892 8.54 + -
Clusterin (apolipoprotein J) 52641 5.89 - +
Hemopexin 51643 6.55 - -
Fibrinogen # chain 51479 5.37 + -
IgM $ chain C region 49276 6.35 - +
Apolipoprotein A-IV 45371 5.28 - +
Apolipoprotein E 36132 5.65 - +
IgG #-1 chain C region 36083 8.46 + +
IgG #-2 chain C region 35878 7.66 + +
Apolipoprotein A-I 30759 5.56 + +
aIsoelectric points calculated from the complete sequence retrieved from the UniProt
database using the built-in pI/MW calculator. ! ! ! ! 
Table 9. Adsorbed proteins identified from THCPSi and HFBII-THCPSi
nanoparticles after 120 minutes of incubation in 100% human plasma.
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6 DISCUSSION
6.1	 DEVELOPMENT OF 18F-RADIOLABELED PSi
PARTICLE TRACERS
6.1.1 Radiolabeling strategy 
The known high affinity of silicon for fluorine made the use of the direct 
nucleophilic substitution with 18F– a lucrative approach for radiolabeling of 
PSi particles, as a silyl hydrogen could be readily replaced by 18F–. Although 
the surface-modified PSi used in this study had been chemically treated to 
remove the initial hydrogen-termination of the freshly prepared PSi surface,
it was expected that enough residual Si–H groups would be present making 
the choice of the radiolabeling strategy a reasonable one. Additionally, other 
silyl substituents such as oxygen or fluorine could be replaced by 18F.
However, because the surface chemistry of the top-down -prepared material 
is not always clearly defined, the presence of such functionalities had to be 
determined using spectroscopic methods alongside the radiolabeling 
18F–synthesis development. Nevertheless, radiolabeling with activated 
/Kryptofix 2.2.2/K+ was achieved with high or satisfactory yields for all of the 
investigated surface-modified PSi materials, corroborating the feasibility of 
the approach. Furthermore, the use of activated [18F]F– directly as the radio­
labeling synthon is advantageous as it shortens the synthesis time, which is 
of particular importance for particulate tracers that often need more time-
consuming purification procedures than conventional radiotracers. 
The selected radiolabeling strategy proved out to be the most effective for 
[18F]THCPSi and [18F]TCPSi, in which RCYs exceeding 80% were achieved.
The Si–Ox termination of TOPSi, however, made it difficult to radiolabel at 
comparable RCYs. This is possibly a result of the relative instability of the 
TOPSi surface at pH > 7, which could contribute to the loss of the radiolabel 
through disintegration of the particles. Furthermore, because the surface of 
TOPSi is hydrophilic, OH– ions in aqueous media are able to penetrare closer 
to the surface leading to eventual hydrolysis of the formed Si–18F bond. The 
two mechanisms, however, cannot be distinguished from one another in this 
experimental setup.
Creation of a Si–18F bond on the PSi surface translated to good to excellent 
radiolabel stability in vitro for all of the investigated materials. Furthermore,
a good in vitro—in vivo correlation was achieved for stability of [18F]THCPSi,
illustrating the predictive value of the selected media. In conclusion, a 
general radiolabeling strategy for the three surface-modified PSi materials 
was successfully developed. Further studies are, however, needed in order to 
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devise a more efficient radiolabeling strategy for TOPSi. Additionally, while 
the developed [18F]THCPSi, [18F]TCPSi, and [18F]TOPSi tracers can be used 
as cores for further surface modifications, new radiolabeling strategies
employing 18F-containing prosthetic groups will be needed for PSi materials 
in which the direct nucleophilic substitution with 18F– is not feasible.
6.1.2 Biofunctionalization with T. reesei HFBII 
Two alternative strategies could have been adopted for the radiolabeling of 
THCPSi nanoparticles modified with T. reesei HFBII. Perhaps the more 
obvious one, from the perspective of a radiochemist, would have been to take 
the already biofunctionalized particles and radiolabel them on the HFBII 
protein layer with for example an isotope of iodine (e.g. 123I, 131I, or 124I), or a 
18F-radiolabeled synthon such as [18F]SFB. However, the post-radiosynthetic 
coating of [18F]THCPSi nanoparticles with HFBII has the advantage that it 
safeguards the possibility to follow the nanoparticles despite the fate of the 
coating in vivo. Therefore, as a pronounced detachment of the HFBII coating 
was seen in vitro in FaSSIF, the only reasonable alternative was to use 
HFBII-coated [18F]THCPSi nanoparticles in the biodistribution studies with 
oral administration. Self-assembly of the HFBII layer on [18F]THCPSi 
nanoparticles was achieved with a simple procedure without compromise to 
the product SA or RCY. The observed rapid desorption and solubilization of 
HFBII in FaSSIF is very likely due to the displacement of the adsorbed 
protein by sodium taurocholate, a surfactant, present in the medium (Galia et 
al., 1998). Because hydrophobin is most probably adsorbed to the THCPSi 
surface through hydrophobic interactions, it is likely that the small surfactant 
molecules could efficiently disrupt these interactions resulting in the 
detachment of the HFBII layer. True intestinal fluid is even more complex 
solution containing a pool of compounds with surfactant properties (e.g. bile 
salts, bicarbonate, and lipolysis products), and therefore we would expect the 
coating to disrupt also in the small intestine in vivo (Shiau, 1987). A similar 
mechanism of displacement could explain the observed slight desorption of 
the HFBII coating in plasma over time. Nevertheless, the overall high 
stability of the HFBII biofunctionalization in biological fluids suggested that 
it would be possible to observe coating-induced changes in THCPSi behavior 
in vivo with the developed HFBII-[18F]THCPSi tracer.
6.1.3 Radiotracer characterization
The properties of a nanomaterial govern the response of biological systems 
towards it. In the present work the physicochemical characterization of the 
developed particle radiotraces was carried out with spectroscopy, DLS, and 
zeta potential measurements. Two fundamental questions in tracer 
development could be resolved with the spectroscopic methods used in the 
study. First, by combining the data gathered from the radiosynthesis 
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development (the effects of solvent, temperature, and acidic conditions) to 
the elemental analysis from XPS of materials radiolabeled with added 19F 
carrier, we were able to establish that the anticipated substitution of a silyl 
hydrogen for 18F– was not feasible for all of the investigated surface-modified 
PSi. Second, from FTIR spectroscopy we were able to tell the impact of the 
radiolabeling conditions to the overall surface chemistry of the investigated 
materials. The importance of the latter is quite obvious from a tracer 
development perspective, because in order to successfully use the developed 
18F-radiolabeled PSi particles as a tracer for PSi behavior, we cannot subject
the particles to a radiolabeling procedure that will alter the surface chemistry 
aside from the incorporation of the 18F isotope. The substitution reaction 
itself is not expected to affect the overall surface chemistry, because the high 
specific activity of cyclotron-produced 18F ensures that the isotope is present 
in nanomolar quantities resulting only in localized aberrations of the 
nanoparticle surface. This was confirmed in this work by the lack of or only 
minor effect by the radiolabeling conditions in either the FTIR spectra or zeta 
potential of [18F]THCPSi. Analogously, particle size and zeta potential 
measurements were primarily employed to verify that the physicochemical 
properties of the THCPSi nanoparticles remained unchanged after the 18F­
radiolabeling and across [18F]THCPSi nanoparticle batches used in the 
biodistribution studies. In conclusion, the 18F-radiolabeled PSi particles 
developed in the present work had comparable physicochemical properties as 
their non-radiolabeled counterparts, and were consequently expected to
exhibit similar behavior in biological systems. 
6.2 TRACER EVALUATION IN BIOLOGICAL SYSTEMS
6.2.1 Biocompatibility 
In nanobiomedicine and biomaterials science, the term biocompatibility 
encompasses several aspects of the interaction between the material and 
biological systems such as body fluids, living cells, and whole organisms. The 
biocompatibility of THCPSi and HFBII-THCPSi was comprehensively 
evaluated in several cell lines representative of the different administration 
routes using assays for cell viability and inflammatory and oxidative stress 
responses together with confocal microscopy. The differences in cellular 
response towards different particle sizes observed in this study underline the 
importance of control over the size distribution of the synthesized drug 
delivery carriers (Jiang et al., 2008). However, the overall cellular response 
towards THCPSi nanoparticles at the tolerated size range was mild,
prompting their use in the biodistribution studies. Biofunctionalization of 
THCPSi nanoparticles with HFBII increased their biocompatibility in AGS 
cells and RAW 264.7 macrophages. In AGS cells, the plausible explanation 
for this is that since the HFBII-THCPSi nanoparticles are hydrophilic,
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indirect cell–nanoparticle interactions mediated by the water layer 
surrounding the hydrated particles are favored over the strong adhesion 
observed for hydrophobic THCPSi that can lead to cytotoxicity (Santos et al.,
2010). Additionally, possibly because of their immune origin, macrophages 
have been shown to be more sensitive to the cytotoxic effects of PSi particles 
than other cell types (Bimbo et al., 2011a). However, even at best, the 
biocompatibility in vitro can be used only to predict the biocompatibility of 
the material in vivo, and complete toxicological evaluation of the PSi 
materials is warranted before their future use as drug delivery carriers at 
therapeutic doses. 
6.2.2 Biodistribution 
Knowledge of the biodistribution of a particulate carrier is paramount to the 
evaluation of its performance as a drug delivery system. The results 
presented here constitute the first studies on the biodistribution of a 18F­
radiolabeled PSi nanocarriers. The half-life of 18F is sufficiently long to allow 
for the imaging of slower physiological processes such as transit in the GI 
tract for up to 6 hours after oral administration of the radiolabeled nano­
particles. Furthermore, radiolabeled nanocarriers are not typically evaluated 
in the oral route, which necessitated the development of the new
methodology for the visualization and quantification of the nanoparticles in 
the GI tract. Here, the ex vivo macroautoradiography proved out to be a 
powerful tool, as it allowed for the precise identification of the different 
regions of the lower GI tract and quantification of the radioactivity at high 
resolution. The same information would have been challenging to extract 
from a PET image. Furthermore, the same radiolabeled tracer could be 
employed to study biodistribution across different levels of organization: 
from within one organ to the whole body. The disadvantage of ex vivo
methods is of course that longitudinal follow-up of a single animal is not 
possible. The methods presented are, however, fully translatable to small 
animal PET imaging studies. The imaging studies would provide important 
information on especially the kinetics of PSi nanoparticle biodistribution and 
elimination after intravenous delivery, and are of particular importance for 
the development of targeted and longer-circulating carriers for intravenous 
use. In conclusion, the biodistribution studies with the 18F-radiolabeled PSi 
particle tracers developed in the present work constitute a new platform for 
evaluation of PSi-based carriers for drug delivery with PET. 
6.2.3 Mucoadhesive and gastroretentive properties of HFBII-THCPSi 
The HFBII-biofunctionalization was shown to bestow mucoadhesive 
properties to THCPSi nanoparticles. Possible mechanisms underlying the 
mucoadhesion in vitro include electrostatic and hydrophobic interactions 
between the nanoparticles and the mucous cell membrane mediated by 
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Discussion
specific amino acid residues on the HFBII layer. Furthermore, the cysteine 
residues in HFBII could form disulfide bonds with thiol groups present in 
certain mucus glycoproteins (Linder et al., 2001, Bernkop-Schnürch et al.,
2006). The contributions of these and their impact on mucoadhesion in vivo,
however, cannot be assigned without further mechanistic studies on the cell– 
nanoparticle interaction that fell out of the scope of the present study.
Nevertheless, support for the mucoadhesion of HFBII-THCPSi also in vivo
was gained from the observed gastric retention of the nanoparticles.
Curiously, the amount of radioactivity retained in the stomach of animals 
dosed with HFBII-[18F]THCPSi nanoparticles appeared to peak in 2–3 hours,
suggesting that it takes time for the particles to come in contact and adhere 
to the gastric mucosa. This is very likely a result of the dynamics of ingestion 
and mixing of the gastric contents in the rat, where the stomach is divided 
into two parts performing distinct functions: the forestomach for storage of
ingested, salivated food, and the glandular stomach in which the digestion 
continues (Gärtner, 2002). It is therefore possible that the nanoparticles 
start to adhere to the mucosa only in the glandular stomach, thus explaining 
the observed peak in the retention of the dosed radioactivity. The offset of 
mucoadhesion and subsequent release of the nanoparticles from the stomach 
is most probably determined by the initial contact time with the gastric 
mucosa, shear forces arising from the mixing of the gastric contents, changes 
in pH, and local mucin turnover, which were not assessed in this study 
(Asane et al., 2008, Silen, 1987, Rubinstein et al., 1994). It needs to be noted
that typically bioadhesion of gastroretentive dosage forms is evaluated in
vitro or in situ in isolated segments of the GI tract, rendering the conditions 
used in this study a rather rigorous test for mucoadhesion. It is thus 
anticipated that the HFBII-THCPSi nanoparticles would have performed 
even better in an isolated model.
In conclusion, the discovery warrants further studies with HFBII-THCPSi 
particles as drug delivery carriers in the oral route. The HFBII-THCPSi 
nanoparticles could have potential utility as a gastroretentive drug delivery 
system for drugs that are either targeted for the stomach for localized action 
(such as antacids or antibiotics against Helicobacter pylori infection), or that 
have a narrow absorption window in the upper small intestine (e.g. L-DOPA) 
and would thus benefit from sustained gastric release (Hoffman et al., 2004). 
Furthermore, the rapid dissolution of the HFBII coating in the small 
intestine is envisioned to be useful in the development of multiparticulate,
biodegradable drug delivery systems.
6.2.4 Fate of HFBII-THCPSi after intravenous administration  
In the present work, biofunctionalization of THCPSi nanoparticles with 
HFBII significantly altered the biodistribution of the nanoparticles between
the liver, spleen, and lungs. Despite comprehensive reports on the formation 
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of the plasma protein corona on a nanoparticle surface and its potential 
implications on biodistribution, the contributions of individual opsonins to 
the sequestration of nanoparticles to the MPS system have proven to be
difficult to address (Dobrovolskaia et al., 2007, Aggarwal et al., 2009, Owens
et al., 2006). Our results corroborate the finding that negatively charged 
nanoparticles are prone to adsorption of plasma proteins with pI values 
residing between 5.5 and 7 (Gessner et al., 2003, Tenzer et al., 2011). Serum 
albumin and fibrinogen, found in this study exclusively on THCPSi, have 
been implicated in the onset of plasma protein corona formation (Göppert et 
al., 2005). Their inclusion to the THCPSi nanoparticle aggregates even after 
120 minutes suggests that they might have contributed to the aggregation of 
the nanoparticles immediately in plasma, and possibly promoted their 
physical removal from the circulation in vivo through splenic filtration and 
entrapment to the lung capillary bed (Moghimi et al., 2001). Smaller HFBII-
THCPSi nanoparticles could have escaped similar extensive splenic filtration,
but because of the decoration of their surface with proteins that are known to 
promote phagocytosis in both “professional” (e.g. Kupffer cells and resident 
macrophages in the spleen) and “non-professional” (e.g. hepatocytes and 
cells of fibroblast origin) phagocytes, they could be more prone to immune 
recognition than THCPSi (Moghimi et al., 2001, Dams et al., 2000, Bartl et
al., 2001, Yan et al., 2005). However, more comprehensive studies on plasma 
protein adsorption onto PSi particles are needed in order to corroborate 
these observations and dissect the roles of the different components of the 
corona to nanoparticle biofate. Nevertheless, our results constitute a starting 
point for development of HFBII-THCPSi -based carriers for targeted drug 
delivery in the intravenous route.
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Summary and concluding remarks
7 SUMMARY AND CONCLUDING REMARKS
 
In summary, radiolabeling with 18F has been established as a robust tool to 
investigate PSi micro- and nanoparticle behavior in vivo. We have shown 
that direct nucleophilic substitution of 18F– to various surface-modified PSi is 
feasible within the limits set by the 109.8-minute half-life of the isotope.
Depending of the surface chemistry, the substitution reaction was shown to 
occur either to a Si–H, Si–O–Si, or Si–F groups on the PSi surface. The 
synthesized Si–18F bond was remarkably stable in physiological conditions 
both in vitro and in vivo, highlighting one of the undisputable strengths of 
the selected radiolabeling strategy. Furthermore, the surface chemistry and 
other properties of the nanoparticles were not changed by the conditions of 
the radiolabeling reaction confirming that they could be used as tracers for 
non-radiolabeled PSi. [18F]THCPSi nanoparticles were shown to exhibit high 
biocompatibility in vitro, prompting their use in the animal studies. Post­
radiosynthetic biofunctionalization of [18F]THCPSi nanoparticles with a self-
assembled layer of a fungal hydrophobin was successfully realized in order to 
develop a tracer for HFBII-THCPSi nanoparticles. Biodistribution studies 
with HFBII-[18F]THCPSi nanoparticles revealed mucoadhesive and gastro­
retentive properties that encourage further studies with the HFBII-bio­
functionalized nanoparticles as drug delivery carriers in the oral route. In 
addition, the HFBII coating markedly altered the plasma protein adsorption 
to THCPSi nanoparticles and consequently their biodistribution after intra­
venous administration, illustrating the importance of the knowledge of 
unmodified drug delivery carrier biodistribution to the development of 
tailored carriers for intravenous delivery.
In conclusion, the studies presented in this work contribute new methodo­
logy for the evaluation of PSi-based materials as drug delivery carriers. The 
developed radiotracers enable the use of sensitive, quantitative, and fully 
translational molecular imaging methods already at the early stages of PSi 
carrier development, thus speeding up the development process and 
discovery of the most promising materials contributing ultimately to the 
realization of the potential of PSi materials for carrier-mediated drug 
delivery. 
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